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A B S T R A C T
Background
This review represents one from a family of three reviews focusing on interventions for drug-using offenders. Many people under the care
of the criminal justice system have co-occurring mental health problems and drug misuse problems; it is important to identify the most
effective treatments for this vulnerable population.
Objectives
To assess the effectiveness of interventions for drug-using offenders with co-occurring mental health problems in reducing criminal activity
or drug use, or both.
This review addresses the following questions.
• Does any treatment for drug-using offenders with co-occurring mental health problems reduce drug use?
• Does any treatment for drug-using offenders with co-occurring mental health problems reduce criminal activity?
• Does the treatment setting (court, community, prison/secure establishment) affect intervention outcome(s)?
• Does the type of treatment affect treatment outcome(s)?
Search methods
We searched 12 databases up to February 2019 and checked the reference lists of included studies. We contacted experts in the field for
further information.
Selection criteria
We included randomised controlled trials designed to prevent relapse of drug use and/or criminal activity among drug-using offenders
with co-occurring mental health problems.
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Data collection and analysis
We used standard methodological procedures as expected by Cochrane .
Main results
We included 13 studies with a total of 2606 participants. Interventions were delivered in prison (eight studies; 61%), in court (two studies;
15%), in the community (two studies; 15%), or at a medium secure hospital (one study; 8%). Main sources of bias were unclear risk of
selection bias and high risk of detection bias.
Four studies compared a therapeutic community intervention versus (1) treatment as usual (two studies; 266 participants), providing
moderate-certainty evidence that participants who received the intervention were less likely to be involved in subsequent criminal activity
(risk ratio (RR) 0.67, 95% confidence interval (CI) 0.53 to 0.84) or returned to prison (RR 0.40, 95% CI 0.24 to 0.67); (2) a cognitive-behavioural
therapy (one study; 314 participants), reporting no significant reduction in self-reported drug use (RR 0.78, 95% CI 0.46 to 1.32), re-arrest for
any type of crime (RR 0.69, 95% CI 0.44 to 1.09), criminal activity (RR 0.74, 95% CI 0.52 to 1.05), or drug-related crime (RR 0.87, 95% CI 0.56 to
1.36), yielding low-certainty evidence; and (3) a waiting list control (one study; 478 participants), showing a significant reduction in return
to prison for those people engaging in the therapeutic community (RR 0.60, 95% CI 0.46 to 0.79), providing moderate-certainty evidence.
One study (235 participants) compared a mental health treatment court with an assertive case management model versus treatment
as usual, showing no significant reduction at 12 months' follow-up on an Addictive Severity Index (ASI) self-report of drug use (mean
difference (MD) 0.00, 95% CI -0.03 to 0.03), conviction for a new crime (RR 1.05, 95% CI 0.90 to 1.22), or re-incarceration to jail (RR 0.79,
95% CI 0.62 to 1.01), providing low-certainty evidence.
Four studies compared motivational interviewing/mindfulness and cognitive skills with relaxation therapy (one study), a waiting list con-
trol (one study), or treatment as usual (two studies). In comparison to relaxation training, one study reported narrative information on
marijuana use at three-month follow-up assessment. Researchers reported a main effect < .007 with participants in the motivational in-
terviewing group, showing fewer problems than participants in the relaxation training group, with moderate-certainty evidence. In com-
parison to a waiting list control, one study reported no significant reduction in self-reported drug use based on the ASI (MD -0.04, 95%
CI -0.37 to 0.29) and on abstinence from drug use (RR 2.89, 95% CI 0.73 to 11.43), presenting low-certainty evidence at six months (31
participants). In comparison to treatment as usual, two studies (with 40 participants) found no significant reduction in frequency of mar-
ijuana use at three months post release (MD -1.05, 95% CI -2.39 to 0.29) nor time to first arrest (MD 0.87, 95% CI -0.12 to 1.86), along with
a small reduction in frequency of re-arrest (MD -0.66, 95% CI -1.31 to -0.01) up to 36 months, yielding low-certainty evidence; the other
study with 80 participants found no significant reduction in positive drug screens at 12 months (MD -0.7, 95% CI -3.5 to 2.1), providing very
low-certainty evidence.
Two studies reported on the use of multi-systemic therapy involving juveniles and families versus treatment as usual and adolescent sub-
stance abuse therapy. In comparing treatment as usual, researchers found no significant reduction up to seven months in drug depen-
dence on the Drug Use Disorders Identification Test (DUDIT) score (MD -0.22, 95% CI -2.51 to 2.07) nor in arrests (RR 0.97, 95% CI 0.70 to
1.36), providing low-certainty evidence (156 participants). In comparison to an adolescent substance abuse therapy, one study (112 par-
ticipants) found significant reduction in re-arrests up to 24 months (MD 0.24, 95% CI 0.76 to 0.28), based on low-certainty evidence.
One study (38 participants) reported on the use of interpersonal psychotherapy in comparison to a psychoeducational intervention. In-
vestigators found no significant reduction in self-reported drug use at three months (RR 0.67, 95% CI 0.30 to 1.50), providing very low-
certainty evidence. The final study (29 participants) compared legal defence service and wrap-around social work services versus legal
defence service only and found no significant reductions in the number of new offences committed at 12 months (RR 0.64, 95% CI 0.07
to 6.01), yielding very low-certainty evidence.
Authors' conclusions
Therapeutic community interventions and mental health treatment courts may help people to reduce subsequent drug use and/or crim-
inal activity. For other interventions such as interpersonal psychotherapy, multi-systemic therapy, legal defence wrap-around services,
and motivational interviewing, the evidence is more uncertain. Studies showed a high degree of variation, warranting a degree of caution
in interpreting the magnitude of effect and the direction of benefit for treatment outcomes.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for drug-using offenders with co-occurring mental health problems
What is the aim?
To identify therapies to reduce drug use and/or criminal activity among criminal justice involved people with mental health problems.
What is the key message?
Therapeutic community interventions and mental health treatment courts may help people to reduce subsequent drug use and/or crim-
inal activity.
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What was studied?
Therapies identified to support criminal justice involved people with mental health and drug misuse problems.
What are the results?
￭ When men engage with a therapeutic community intervention compared to treatment as usual, they are probably less likely to be re-
arrested or return to prison (moderate-certainty).
￭ When women engage with a therapeutic community intervention compared to a cognitive-behavioural course, they may not be more
likely to reduce drug use, or become involved in criminal activity/drug-related crimes (low-certainty).
￭ When men engage with a therapeutic community compared to no intervention, they are probably less likely to return to prison (mod-
erate-certainty).
￭ When juveniles engage with a mental health court compared to treatment as usual, they may be less likely to commit a new crime, return
to prison, or take drugs (low-certainty).
￭ When juveniles engage with motivational interviewing/mindfulness and cognitive skills, they are probably less likely to show fewer prob-
lems than receiving relaxation training (moderate-certainty).
￭ When people engage with motivational interviewing/mindfulness and cognitive skills, they may not be more likely to report a reduc-
tion/abstinence from drug use when compared to a waiting list control (low-certainty).
￭ We are uncertain whether people engaged in motivational interviewing/mindfulness and cognitive skills are not more likely to report a
reduction in marijuana use, a positive drug test, or to be re-arrested when compared to treatment as usual (very low-certainty).
￭ When families and juveniles engage in multi-systemic therapy, they may be more likely to report a reduction in drug dependence or to
be re-arrested in comparison to treatment as usual or group substance abuse therapy (low-certainty).
￭ We are uncertain whether people involved in interpersonal psychotherapy are not more likely to use drugs again in comparison to a
psychoeducational intervention (very low-certainty).
￭ We are uncertain whether people involved in legal defence service and wrap-around services are not more likely to commit new offences
in comparison to a legal defence service only (very low-certainty).
Sources of funding included government institutes, research bodies, or charities.
How up-to-date is this review?
February 2019.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Therapeutic community compared to treatment as usual for drug-using oenders with co-occurring
mental illness
Therapeutic community compared to treatment as usual for drug-using offenders with co-occurring mental health problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: prison 
Intervention: therapeutic community
Comparison: treatment as usual
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow up
Certainty of
the evidence
(GRADE)
Relative effect
(95% CI)
Risk with treatment
as usual
Risk difference with therapeutic commu-
nity
Study populationRe-arrests
assessed with official records
Follow-up: 12 months
266
(2 RCTs)
⊕⊕⊕⊝
MODERATEa
RR 0.67
(0.53 to 0.84)
98 per 100 32 fewer per 100
(46 fewer to 16 fewer)
Study populationRe-incarceration
assessed with official records
Follow-up: 12 months
266
(2 RCTs)
⊕⊕⊕⊝
MODERATEa
RR 0.40
(0.24 to 0.67)
59 per 100 36 fewer per 100
(45 fewer to 20 fewer)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one for risk of bias (blinding and selective reporting).
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Summary of findings 2.   Therapeutic community and aAercare compared to cognitive behavioural skills for drug using women oenders with co-
occurring mental illness
Therapeutic community and aftercare compared to cognitive-behavioural skills for drug-using women offenders with co-occurring mental health problems
Patient or population: drug-using women offenders with co-occurring mental health problems
Setting: prison
Intervention: therapeutic community and aftercare
Comparison: cognitive-behavioural skills
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of
the evidence
(GRADE)
Relative ef-
fect
(95% CI) Risk with cogni-
tive-behavioural
skills
Risk difference with therapeutic
community and aftercare
Study populationSelf-reported drug use
Follow-up: 6 months
314
(1 RCT)
⊕⊝⊝⊝
LOWa,b
RR 0.78
(0.46 to 1.32)
17 per 100 4 fewer per 100
(9 fewer to 6 more)
Study populationRe-arrest for any type of crime
assessed with Colorado Department of Corrections
Record Information System (CDOC-RIS)
Follow-up: 6 months
314
(1 RCT)
⊕⊝⊝⊝
LOWa,b
RR 0.69
(0.44 to 1.09)
33 per 100 10 fewer per 100
(19 fewer to 3 more)
Study populationCriminal Activity
assessed with Colorado Department of Corrections
Record Information System (CDOC-RIS)
Follow-up: 6 months
314
(1 RCT)
⊕⊝⊝⊝
LOWa,b
RR 0.74
(0.52 to 1.05)
33 per 100 9 fewer per 100
(16 fewer to 2 more)
Study populationDrug-related crime
assessed with Colorado Department of Corrections
Record Information System (CDOC-RIS)
Follow-up: 6 months
314
(1 RCT)
⊕⊝⊝⊝
LOWa,b
RR 0.87
(0.56 to 1.36)
21 per 100 3 fewer per 100
(9 fewer to 8 more)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
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Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aUnclear reporting in the paper raises concerns about the potential high risk of bias with regards to blinding and methods used in the randomisation procedure; we downgraded
by one.
bOne study with 95% confidence intervals through the line of no effect.
 
 
Summary of findings 3.   Therapeutic community compared to waiting list control for drug-using oenders with co-occurring mental illness
Therapeutic community compared to waiting list control for drug-using offenders with co-occurring mental health problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: prison
Intervention: therapeutic community
Comparison: waiting list control
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of
the evidence
(GRADE)
Relative ef-
fect
(95% CI) Risk with waiting
list control
Risk difference with therapeutic
community
Study populationReturn to prison (recidivism) post parole
assessed with California Department of Correction's
computerised Offender Based Information System
Follow-up: 36 months
478
(1 RCT)
⊕⊕⊕⊝
MODERATEa
RR 0.60
(0.46 to 0.79)
40 per 100 16 fewer per 100
(21 fewer to 8 fewer)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one for risk of bias (randomisation process, concealment, and selective reporting).
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Summary of findings 4.   Mental health treatment court with assertive case management model compared to treatment as usual for drug-using
oenders with co-occurring mental illness
Mental health treatment court with assertive case management model compared to treatment as usual for drug-using offenders with co-occurring mental health
problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: court
Intervention: mental health treatment court with assertive case management model
Comparison: treatment as usual
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of
the evidence
(GRADE)
Relative ef-
fect
(95% CI) Risk with treatment
as usual
Risk difference with mental health treat-
ment court with assertive case manage-
ment model
Study populationConviction for a new crime
assessed with data from probation office
Follow-up: 12 months
235
(1 RCT)
⊕⊝⊝⊝
LOWa
RR 1.05
(0.90 to 1.22)
72 per 100 4 more per 100
(7 fewer to 16 more)
Study populationRe-incarceration to jail
assessed with data from probation office
Follow-up: 12 months
235
(1 RCT)
⊕⊝⊝⊝
LOWa
RR 0.79
(0.62 to 1.01)
71 per 100 15 fewer per 100
(27 fewer to 1 more)
Self-reported drug use
assessed with Addiction Severity Index (ASI)
Follow-up: 12 months
235
(1 RCT)
⊕⊝⊝⊝
LOWa
- Mean self-reported
drug use was 0.08
MD 0.00
(-0.03 lower to 0.03 higher)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one for risk of bias (allocation concealment and blinding of assessors) and by one for imprecision.
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Summary of findings 5.   Motivational interviewing/mindfulness and cognitive skills compared to relaxation training for drug-using oenders with co-
occurring mental illness
Motivational interviewing/mindfulness and cognitive skills compared to relaxation training for drug-using offenders with co-occurring mental health problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: prison
Intervention: motivational interviewing and cognitive skills
Comparison: relaxation training
Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of the
evidence
(GRADE)
Impact
Self-reported
marijuana use
continuous
181
(1 RCT)
MODERATEa This study compared cognitive skills to a relaxation training intervention for adolescents in prison with de-
pressed mood. Researchers measured marijuana use at 3-months follow-up assessment using the Risks and
Consequences Questionnaire (RCQ). They report a main effect < .007, with participants in the motivational
interviewing group showing fewer problems than participants in the relaxation training group.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one for unclear risk of bias (random allocation and blinding).
 
 
Summary of findings 6.   Motivational interviewing/mindfulness and cognitive skills compared to waiting list control for drug-using oenders with co-
occurring mental illness
Motivational interviewing/mindfulness and cognitive skills compared to waiting list control for drug-using offenders with co-occurring mental health problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: prison
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Intervention: motivational interviewing and cognitive skills
Comparison: waiting list control
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of
the evidence
(GRADE)
Relative ef-
fect
(95% CI) Risk with waiting list
control
Risk difference with motivational inter-
viewing and cognitive skills
Self-reported drug use
assessed with Addiction Severity Index (ASI)
composite drug score across 13 items of
drug use in the last 30 days
Follow-up: 6 months
31
(1 RCT)
⊕⊕⊝⊝
LOWa
- Mean self-reported drug
use was 0.44
MD -0.04 lower
(-0.37 lower to 0.29 higher)
Study populationAbstinence from drug use
Follow-up: 6 months
31
(1 RCT)
⊕⊕⊝⊝
LOWa
RR 2.89
(0.73 to 11.43)
15 per 100 29 more per 100
(4 fewer to 160 more)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by two for optimal information size not met.
 
 
Summary of findings 7.   Motivational interviewing/mindfulness and cognitive skills compared to treatment as usual for drug-using oenders with co-
occurring mental illness
Motivational interviewing/mindfulness and cognitive skills compared to treatment as usual for drug-using offenders with co-occurring mental health problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: medium secure hospital and jail
Intervention: motivational interviewing and cognitive skills
Comparison: treatment as usual
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0
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of
the evidence
(GRADE)
Relative ef-
fect
(95% CI) Risk with treatment as usual Risk difference with motiva-
tional interviewing and cogni-
tive skills
Self-reported frequency of marijuana use
assessed with TCU-CRTF (Texas Christian Uni-
versity: Correctional Residential Treatment
Form)
Scale from 0 to 32
Follow-up: 3 months
40
(1 RCT)
⊕⊕⊝⊝
VERY LOWa,b
- Mean self-reported frequency of
marijuana use was 1.50
MD -1.05 lower
(-2.39 lower to 0.29 higher)
Arrest frequency post release
assessed with official police records
Follow-up: 36 months
40
(1 RCT)
⊕⊕⊝⊝
VERY LOWa,b
- Mean arrest frequency post re-
lease was 1.47
MD -0.66 lower
(-1.31 lower to -0.01 lower)
Time to first arrest or offence
assessed with official police records
Follow-up: 36 months
40
(1 RCT)
⊕⊕⊝⊝
VERY LOWa,b
- Mean time to first arrest or of-
fence was 1.6
MD 0.87 higher
(-0.12 lower to 1.86 higher)
Positive drug screen or refusal to provide a
urine sample
assessed with urine sample
Scale from negative to positive
Follow-up: 12 months
84
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b
- Mean positive drug screen or re-
fusal to provide a urine sample
was 3.25
MD -0.7 lower
(-3.5 lower to 2.1 higher)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by two for optimal size not met.
bDowngraded by one for risk of bias (incomplete outcome measures).
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Summary of findings 8.   Multi-systemic therapy involving family and juveniles compared to treatment as usual for drug-using oenders with co-
occurring mental illness
Multi-systemic therapy involving family compared to treatment as usual for drug-using offenders with co-occurring mental health problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: community
Intervention: multi-systemic therapy involving family
Comparison: treatment as usual
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of
the evidence
(GRADE)
Relative ef-
fect
(95% CI) Risk with treatment as
usual
Risk difference with multi-systemic ther-
apy involving family
Drug dependence
assessed with DUDIT questionnaire
Scale from 0 to 44
Follow-up: 7 months
156
(1 RCT)
⊕⊕⊝⊝
LOWa
- Mean drug dependence
was 3.55
MD -0.22 lower
(-2.51 lower to 2.07 higher)
Study populationArrested
assessed by corroborating with police data
Follow-up: 7 months
158
(1 RCT)
⊕⊕⊝⊝
LOWa
RR 0.97
(0.70 to 1.36)
47 per 100 1 fewer per 100
(14 fewer to 17 more)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one for risk of bias (blinding measures) and downgraded by one for imprecision.
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Summary of findings 9.   Multi-systemic therapy involving family compared to group substance abuse therapy for drug-using adolescents with co-
occurring mental illness
Multi-systemic therapy involving family compared to group substance abuse therapy for drug-using adolescents with co-occurring mental health problems
Patient or population: drug-using adolescents with co-occurring mental health problems
Setting: court
Intervention: multi-systemic therapy involving family
Comparison: group substance abuse therapy
Anticipated absolute effects* (95% CI)Outcomes № of participants
(studies)
Follow-up
Certainty of
the evidence
(GRADE)
Relative ef-
fect
(95% CI) Risk with group substance abuse
therapy
Risk difference with multi-systemic therapy
involving family
Arrests
Follow-up: range 6
months to 24 months
112
(1 RCT)
⊕⊕⊝⊝
LOWa
- Mean arrests were 1.19 SD MD -0.24 SD lower
(-0.76 lower to 0.28 higher)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial; SD: standard deviation.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by one for risk of bias (selective reporting of outcomes) and by one for imprecision.
 
 
Summary of findings 10.   Interpersonal psychotherapy compared to a psychoeducational intervention for drug-using oenders with co-occurring
mental illness
Interpersonal psychotherapy compared to a psychoeducational intervention for drug-using offenders with co-occurring mental health problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: prison
Intervention: interpersonal psychotherapy
Comparison: psychoeducational intervention
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Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of the
evidence
(GRADE)
Relative effect
(95% CI)
Risk with a psychoeducation-
al intervention
Risk difference with interpersonal psy-
chotherapy
Study populationSubstance abuse relapse
post release
Follow-up: 3 months
38
(1 RCT)
⊕⊕⊝⊝
VERY LOWa,b
RR 0.67
(0.30 to 1.50)
47 per 100 16 fewer per 100
(33 fewer to 24 more)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by two for optimal size not met.
bDowngraded by one for risk of bias (selective reporting outcomes).
 
 
Summary of findings 11.   Legal defence service and wrap-around social work services compared to legal defence service only for drug-using
oenders with co-occurring mental illness
Legal defence service and wrap-around social work services compared to legal defence service only for drug-using offenders with co-occurring mental health
problems
Patient or population: drug-using offenders with co-occurring mental health problems
Setting: court
Intervention: legal defence service and wrap-around social work services
Comparison: legal defence service only
Anticipated absolute effects* (95% CI)Outcomes № of partici-
pants
(studies)
Follow-up
Certainty of the
evidence
(GRADE)
Relative effect
(95% CI)
Risk with legal defence
services only
Risk difference with legal defence services and wrap-
around social work services
Committing new
offences
29
(1 RCT)
⊕⊕⊝⊝
VERY LOWa,b
RR 0.64
(0.07 to 6.01)
Study population
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Follow-up: 12
months
1 per 100 2 fewer per 100
(0 fewer to 2 fewer)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by two for optimal size not met.
bDowngraded for risk of bias (incomplete outcome data).
 
C
o
ch
ra
n
e
L
ib
ra
ry
T
ru
ste
d
 e
v
id
e
n
ce
.
In
fo
rm
e
d
 d
e
cisio
n
s.
B
e
tte
r h
e
a
lth
.
  
C
o
ch
ra
n
e D
a
ta
b
a
se o
f S
ystem
a
tic R
e
vie
w
s
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
B A C K G R O U N D
This review is part of a family of three reviews providing a close
examination of what works in reducing drug use and criminal ac-
tivity among drug-using offenders. These three reviews report on
trials generating several publications and numerous comparisons
(Perry forthcominga; Perryforthcomingc). Two of the three reviews
represent a specific interest in pharmacological interventions and
interventions for female offenders. All three reviews stem from a
previous Cochrane systematic review (Perry 2006). We consider
the effectiveness of interventions based on two key outcomes -
drug use and criminal activity. We have presented here the revised
method for this individual review, focusing on the impact of inter-
ventions for drug-using offenders with co-occurring mental health
problems.
Description of the condition
People involved in the criminal justice system are more likely to
experience mental health problems. Many studies report different
prevalence figures dependent upon the methods used to estimate
prevalence (Fazel 2016). Some studies report generic figures that
represent all serious mental health problems - e.g. over half (64%)
of jail inmates in the United States reporting serious mental health
problems (Glase 2006) - and others attempt to break down different
types of mental health diagnoses (e.g. psychosis vs major depres-
sion). In a systematic review of 33,000 prisoners, one in seven pris-
oners had major depression or psychosis, with little change in rates
of diagnoses over the past three decades (Fazel 2012).
Differences in the prevalence of mental health problems differen-
tiate between males and females and by age. One study of mental
health problems in jails found that more women than men (31%
and 14.5%, respectively) have a serious mental health problem
(Steadman 2009), and one estimate suggests that two-thirds of ju-
veniles in detention custody have a mental health disorder severe
enough to limit their ability to function (Shufelt 2006). Moreover,
violent female offenders were found to be five times more likely
than male offenders to present with anxiety disorders (Waserman
2005). Other studies have reported that a greater proportion of peo-
ple who have mental health problems are more likely to be arrested
compared with the general population (Lamb 1998).
We also know that rates of comorbidity between mental health
problems and substance misuse are high (Butler 2011). Such co-
morbidity worsens the prognosis of the individual psychiatric dis-
order and increases the likelihood of repeat offending and prema-
ture mortality after release (Chang 2015). Despite these difficulties,
it is unknown how well interventions devised to deal with this co-
morbidity address these problems (Fazel 2002).
Description of the intervention
Many different treatments for substance misuse (e.g. detoxifica-
tion, therapeutic communities) have been adopted for use in the
criminal justice system. This review includes any intervention that
was designed to reduce, eliminate, or prevent relapse to drug use
or criminal activity, or both. This goal has resulted in the inclu-
sion of a wide range of treatments, including mental health treat-
ment courts with an assertive case management model, thera-
peutic communities, motivational interviewing (MI) with cognitive
skills, use of multi-systemic/multi-dimensional therapy involving
families and mindfulness training, legal defence service with wrap-
around social services, and interpersonal psychotherapy .
Case management evolved traditionally to address the needs of
prisoner re-entry programmes covering employment, education,
health, housing, and family support via assessment and connec-
tion of clients with appropriate services (Austin 1994). Case man-
agement in the United States has been applied in Treatment Ac-
countability for Safer Communities programmes (Marlowe 2003b);
it has shown initial effectiveness but without systematic evidence in
support of the process. In the United Kingdom, similar wrap-around
service provision was developed in the 1980s in an attempt to pro-
vide services that were more comprehensive by using a 'joined up'
approach (Synder 2012). Wrap-around service provision requires a
team-based approach that includes the young person, the family,
and service providers in developing, implementing, and evaluating
each part of any support plan (Wilson 2008).
Mental health treatment courts help to link offenders who would
ordinarily be prison-bound to long-term community-based treat-
ment. They rely on mental health assessments, individualised
treatment plans, and ongoing judicial monitoring to address both
the mental health needs of offenders and the public safety con-
cerns of communities. Like other problem-solving courts such as
drug courts, domestic violence courts, and community courts,
mental health courts seek to address the underlying problems
that contribute to criminal behaviour. Mental health courts share
characteristics with crisis intervention teams, jail diversion pro-
grammes, specialised probation and parole caseloads, and a host
of other collaborative initiatives intended to address the significant
overrepresentation of people with mental illness in the criminal
justice system.
Since the 1960s, therapeutic community interventions have been
used in the United States in combination with work release pro-
grammes to rehabilitate offenders via a supportive environment
over a relatively long period. Therapeutic community interventions
specifically providing aftercare have modest effects on the reduc-
tion of recidivism and drug use (Mitchell 2012a; Pearson 1999), but
less is known about the impact of using such schemes with people
who have mental health and drug misuse problems that co-occur
(e.g. Sacks 2008).
Cognitive-behavioural approaches, including self-monitoring,
goal-setting, self-control training, interpersonal skills training, re-
lapse prevention, group work, and lifestyle modification, have
shown signs of success (Lipsey 2007). Previous research based on
systematic reviews has excluded evaluations focusing specifically
on the needs of drug-using offenders and/or mentally disordered
offenders, but not for people with co-occurring mental health and
drug misuse problems. Motivatonal interviewing techniques are of-
ten employed to promote retention in treatment and are aimed
at enhancing motivational change and reducing subsequent re-of-
fending (McMurran 2009; Smedslund 2011).
Multi-systemic/multi-dimensional therapy (MST/MDST) consists of
intensive family- and community-based treatment provided to
adolescents with serious clinical, social, and emotional difficulties.
Research on the effectiveness of MST has failed to produce find-
ings that MST is more effective than other services in preventing re-
strictive out-of-home living arrangements, reducing arrests or con-
victions, or improving life and family functioning (Littell 2005). The
transferability of such schemes has been questioned with variable
Interventions for drug-using oenders with co-occurring mental health problems (Review)
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findings when employed in different countries and contexts (Bogt
2006). MDST has also been employed via the juvenile drug court
model, which is designed to address the link between substance
abuse and criminal activity; it is compared in current work to man-
ualised group-based substance abuse treatment (adolescent group
treatment (AGT)) (Dakof 2015).
Despite growing knowledge about the effectiveness of treatment
programmes for offenders, it appears that no recent systematic re-
view evidence has focused on the effectiveness of treatment for
offenders with drug misuse and co-occurring mental health prob-
lems.
How the intervention might work
Interventions delivered to drug-using offenders under the care of
the criminal justice system have varied over time. Case manage-
ment is used to describe what amounts to a range of diverse prac-
tices and supervision models spanning several different services,
including probation. Examples of case management have been
used to co-ordinate and integrate all aspects of community su-
pervision, from initial offender needs assessment through to pro-
gramme delivery and intended completion of the order or sentenc-
ing requirement (Partridge 2004). Similarily, wrap-around care has
several strengths in its approach, including the family-centred and
culturally sensitive tailoring of each service plan to needs, values,
and talents of the individual person (Synder 2012).
Mental health treatment courts aim to identify clients early on in
the criminal process, either at the jail or by court sta- such as pretri-
al service officers or social workers in the public defender's office.
Most courts have criteria related to what types of charges, criminal
histories, and diagnoses will be accepted. For example, a court may
accept only defendants charged with misdemeanours who have no
history of violent crimes, and who have an Axis I diagnosis based
on recognised diagnostic criteria. Defendants who fit the criteria
based on the initial screening are usually given a more compre-
hensive assessment to determine their interest in participating and
their community treatment needs. Defendants who agree to par-
ticipate receive a treatment plan and other community supervision
conditions. Cases are dismissed or the sentence is greatly reduced
for those who adhere to their treatment plan for the agreed upon
time, usually between six months and two years.
Since the 1960s, therapeutic community interventions have been
used in the United States in combination with work release pro-
grammes to rehabilitate offenders via a supportive environment
over a relatively long period. This usually encompasses the tran-
sition between being in prison and working within the communi-
ty (Prendergast 2011). The ethos of a therapeutic community inter-
vention is to focus on treatment for the whole self (not on the drug
abuse per se) and underlying symptomatic problems, with resi-
dents instrumental in running the therapeutic community (Mitchell
2012a). These interventions are usually based on group activities
provided to address long-term mental illness, personality disor-
ders, and drug addiction. The approach is usually residential, with
clients and therapists living together.
Cognitive-behavioural therapy (CBT) approaches using pro-
grammes based on psychological theory have been employed to
try to help people address their offending behaviour and general-
ly have received good support from the literature in their reduc-
tion of recidivism. This therapy is often described as a psychoso-
cial intervention that aims to improve mental health. CBT focuses
on challenging and changing unhelpful cognitive distortions (e.g.
thoughts, beliefs, attitudes) and behaviours, improving emotional
regulation, and developing personal coping strategies that target
solving current problems. Originally, it was designed to treat de-
pression, but its uses have been expanded to include treatment of
various mental health conditions, including anxiety.
Interpersonal psychotherapy (IPT) is a brief, attachment-focused
psychotherapy that centres on resolving interpersonal problems
and achieving symptomatic recovery. It is an empirically supported
treatment (EST) that follows a highly structured and time-limited
approach and is intended to be completed within 12 to 16 weeks.
IPT is based on the principle that relationships and life events im-
pact mood, and that the reverse is also true.
Miller and Rollnick developed motivational interviewing as a
process to motivate change in substance abusers (Miller 1991).
This technique uses different strategies such as expressing em-
pathy, avoiding arguing for change, and working on ambivalence
to strengthen commitment to change. Meta-analyses support the
use of motivational interviewing as a stand-alone treatment and
in combination with more intensive programmes (Vasilaki 2006).
Linked to this idea of commitment to change is the idea of self-con-
trol, which has established links between substance use and an-
tisocial behaviour (Malouf 2014). The theory suggests that use of
mindfulness involves greater self-awareness, which may promote
thoughtful rather than reactive responding and might help to im-
prove mood and problem behaviour (Shonin 2013).
Why it is important to do this review
Many people who are under the care of the criminal justice system
have co-occurring mental health problems and drug misuse prob-
lems. Although previous research has broadly evaluated treatment
programmes for offenders, we know little about the challenges,
treatments, and rehabilitation opportunities for offenders with co-
occurring mental health and drug misuse problems. We therefore
believe that an evaluation of existing evidence on the impact of
interventions for drug-using offenders with co-occurring mental
health problems might be helpful in identifying treatments for re-
ducing drug use and criminal activity in this vulnerable population.
O B J E C T I V E S
To assess the effectiveness of interventions for drug-using offend-
ers with co-occurring mental health problems in reducing criminal
activity or drug use, or both.
This review addresses the following questions.
• Does any treatment for drug-using offenders with co-occurring
mental health problems reduce drug use?
• Does any treatment for drug-using offenders with co-occurring
mental health problems reduce criminal activity?
• Does the treatment setting (court, community, prison/secure
establishment) affect intervention outcome(s)?
• Does the type of treatment affect treatment outcome(s)?
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We included people involved in the criminal justice system with
co-occurring mental health problems and drug misuse problems
regardless of gender, age, or ethnicity. Drug misuse included any
study that referred to participants who used occasionally, were de-
pendent, or were known to abuse drugs. We defined offenders as
people who were involved in the criminal justice system. Individu-
als could reside in special hospitals, prisons, or the community or
were diverted from court or placed on arrest referral schemes for
treatment. The study setting could change throughout the process
of the study. For example, people involved in the criminal justice
system could begin in prison but progress through a work release
project into a community setting. We judged offenders to have co-
occurring mental health problems when the paper explicitly stated
this. We used several different mechanisms to identify study sam-
ples with mental health problems, including:
• diagnostic gold standard tests such as criteria of the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV), or the International Statistical Classification of Diseases and
Related Health Problems, Tenth Revision (ICD-10);
• the nature of the intervention (e.g. mental health court); and/or
• study authors' descriptions of participants as having a "history
of psychiatric health problems" or a "serious mental disorder"
with co-occurring substance misuse.
Types of interventions
Included interventions were designed, wholly or in part, to elimi-
nate or prevent relapse to drug use or criminal activity, or both,
among participants. We included a range of interventions in the re-
view.
Experimental interventions included in the review
• Any pharmacological intervention (e.g. buprenorphine,
methadone)
• Any psychosocial intervention (e.g. therapeutic community,
case management, cognitive-behavioural therapy, interperson-
al psychotherapy, motivational interviewing)
Control interventions included in the review
• No treatment or waiting list control
• Minimal and/or alternative treatment (e.g. reporting use of a
similar but less intense intervention, using a different theoreti-
cal approach with the same components and/or a different al-
ternative intervention)
• Treatment as usual (included any study that reported a com-
bination and/or component of (1) a psychologically based in-
tervention (e.g. anger management, motivational interviewing,
counselling, aggression replacement, family therapy), (2) an ed-
ucational programme (e.g. health, substance abuse education
on risky behaviour), and/or (3) life skills (e.g. financial planning,
employment skills, computer skills, interpersonal skills in inter-
views)
Types of outcome measures
Primary outcomes
When papers reported several different follow-up periods, we re-
ported the longest period, as we believe this measure provides the
most conservative estimate of effectiveness. We provided:
• drug use measures reported as:
* self-reported drug use (unspecified drug, specific drug use
not including alcohol, Addiction Severity Index composite
scores); or
* biological drug use (measured by drugs testing urine or
analysing hair); and
• criminal activity as measured by:
* self-reported or officially reported criminal activity (includ-
ing arrest for any offence, drug offences, and/or re-incarcer-
ation).
Search methods for identification of studies
Electronic searches
Updated searches identified records from 2014 to 6 February 2019.
• Cochrane Central Register of Controlled Trials (CENTRAL; issues
to February 2019).
• MEDLINE (1966 to February 2019).
• Embase (1980 to February 2019).
• PsycINFO (1978 to February 2019).
• SciSearch (Science Citation Index) (1974 to February 2019).
• Social SciSearch (Social Science Citation Index) (1972 to Febru-
ary 2019).
• Applied Social Sciences Index and Abstracts (ASSIA; 1987 to Feb-
ruary 2019).
• National Technical Information Service (NTIS; 1964 to March
2014).a
• Sociological Abstracts (1963 to March 2014).b
• Healthcare Management Information Consortium (HMIC; to Feb-
ruary 2019).
• Public Affairs Information Service (PAIS; 1972 to February 2019).
• Criminal Justice Abstracts (1968 to February 2019).
• Latin American Caribbean Health Sciences Literature (LILACS;
2004 to February 2019).
• Current Controlled Trials (December 2009).c
• SPECTR (March 2004).d
• Cumulative Index to Nursing and Allied Health Literature (CIN-
HAL)plus (up until February 2019).
aPaid access only - insufficient resources to search.
bNot available to search through York University.
cNo longer available to search.
dNo public access through Campbell Collaboration website, which
previously hosted the database.
To update the review, we restricted the search to studies that were
published since the end date of the previous search (May 2014). We
did not search several original databases indicated by the key at
the end of the database list. One database (NTIS) was fee charg-
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ing, and the other three databases (Sociological Abstracts, Current
Controlled Trials, and SPECTR) were not available for searching due
to changes in the provision of databases through the University of
York.
We developed search strategies for each database to exploit the
search engine most effectively and to make use of any controlled
vocabulary. We included methodological search filters designed to
identify RCTs. Whenever possible, we used filters retrieved from the
InterTASC Information Specialists' Sub-Group (ISSG) Search Filter
Resource site (www.york.ac.uk/inst/crd/intertasc/). If filters were
unavailable from this site, we substituted search terms based on ex-
isting versions. We did not place any language restrictions on iden-
tification and inclusion of studies in the review.
We have listed details of the update search strategies and results
and the websites searched in Appendix 1, Appendix 2, Appendix 3,
Appendix 4, Appendix 5, Appendix 6, Appendix 7, Appendix 8, Ap-
pendix 9, Appendix 10, and Appendix 11.
Searching other resources
Reference checking
We scrutinised the reference lists of all retrieved articles for addi-
tional references and searched the catalogues of relevant organi-
sations.
Personal communication
We sought out experts for their knowledge of other published or
unpublished studies relevant to the review.
Data collection and analysis
Selection of studies
A team of review authors independently inspected the search hits
by reading the titles and abstracts. Each potentially relevant study
was obtained as a full-text article. Each article was independently
assessed for inclusion. In the case of discordance, a third indepen-
dent review author arbitrated. One review author undertook trans-
lation of articles not written in the English language.
We divided the screening process into two key phases. Phase one
used eight key questions as reported in the original review.
Prescreening criteria: phase one
• Is the document an empirical study? If not, exclude the docu-
ment
• Does the study evaluate an intervention, a component of which
is designed to reduce, eliminate, or prevent relapse with drug-
using offenders?
• Are participants referred by the criminal justice system at base-
line?
• Does the study report pre- and post-programme measures of
drug use?
• Does the study report pre- and post-programme measures of
criminal behaviour?
• Is the study an RCT?
• Do the outcome measures refer to the same length of follow-up
for the two groups?
Papers included after phase one screening were then scrutinised
for further assessment.
Prescreening criteria: phase two
• Does the study population comprise wholly participants with di-
agnosed mental health problems using DSM-IV or ICD-10 diag-
nostic criteria? if yes, include the document
• Does the study population comprise wholly participants identi-
fied on screening to have a mental health problem(s) based on
intervention eligibility (e.g. mental health court)? if yes, include
the document
• When the full study population does not comprise offenders
with diagnosed or presumed mental health problems, are sep-
arate results given for those participants with mental health
problems? if no, exclude the document
Data extraction and management
We used data extraction forms to standardise the reporting of da-
ta from all studies obtained as potentially relevant. Two review
authors independently extracted data and subsequently checked
them for agreement. The narrative tables presented study details
(e.g. author, year of publication, country of study origin), study
methods (e.g. random assignment), participants (e.g. number in
sample, age, gender, ethnicity, age, mental health status), interven-
tions (e.g. description, duration, intensity, setting), outcomes (e.g.
description, follow-up period, reporting mechanism), and notes
(e.g. country, funding).
Assessment of risk of bias in included studies
The team of review authors independently assessed risk of bias of
all included studies using the 'Risk of bias' assessment criteria rec-
ommended in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011).
The recommended approach for assessing risk of bias in studies in-
cluded in Cochrane Reviews involves a two-part tool that address-
es four specific domains, namely, sequence generation and alloca-
tion concealment (selection bias), blinding of outcome assessors
(detection bias), incomplete outcome data (attrition bias), and se-
lective outcome reporting (reporting bias). The first portion of the
tool involves describing what was reported to have happened in the
study. The second portion of the tool involves assigning a judge-
ment related to the risk of bias for that entry, in terms of low, high,
or unclear risk. To make these judgements, we used the criteria in-
dicated by the Cochrane Handbook for Systematic Reviews of Inter-
ventions, as adapted to the addiction field. See Appendix 12 for de-
tails.
The domains of sequence generation and allocation concealment
(avoidance of selection bias) were addressed in the tool by a single
entry for each study.
Participants and personnel cannot be blinded to the type of inter-
vention; moreover, we think that being aware of receiving a psy-
chosocial treatment is in itself part of the therapeutic effect; for
these reasons, we did not assess risk of performance bias.
Detection bias was considered separately for objective outcomes
(e.g. dropout, use of substance of abuse measured by urine analy-
sis, participants relapsed at end of follow-up, participants engaged
in further treatments) and subjective outcomes (e.g. duration and
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severity of signs and symptoms of withdrawal, participant self-re-
ported use of substance, side effects, social functioning as integra-
tion at school or at work, family relationship).
Incomplete outcome data (avoidance of attrition bias) was consid-
ered for all outcomes except for dropout from treatment, which is
very often the primary outcome measure in trials on addiction.
For studies identified in the search, the review authors attempted
to contact study authors to establish whether a study protocol was
available.
Measures of treatment eect
The mean differences (MD) with 95% confidence intervals (CIs) was
used for continuous outcomes measured on the same scale, and
the standardised mean difference (SMD) was used for continuous
outcomes measured on different scales. Higher scores for continu-
ous measures are representative of greater harm. We presented di-
chotomous outcomes as risk ratios (RRs), with 95% CIs.
Unit of analysis issues
To avoid double-counting of outcome measures (e.g. arrest, parole
violation) and follow-up periods (e.g. 12 months, 18 months), we
checked all trials to ensure that multiple studies reporting the same
evaluation did not contribute towards multiple estimates of pro-
gramme effectiveness. We followed Cochrane guidance, and where
appropriate, we combined intervention and control groups to cre-
ate a single pair-wise comparison. When this was not appropriate,
we selected one treatment arm and excluded the others.
Dealing with missing data
We attempted to contact study authors via email when we noted
missing data in the original publication.
Assessment of heterogeneity
We assessed heterogeneity using the I2 statistic and the Chi2 sta-
tistic (Higgins 2011). We regarded heterogeneity as substantial if I2
was greater than 50% or if the P value was lower than 0.10 for the
Chi2 test for heterogeneity (Deeks 2017). In keeping with the guid-
ance provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks 2017), we distinguished the following values
to denote no important heterogeneity and moderate, substantial,
and considerable heterogeneity, respectively: 0% to 40%, 30% to
60%, 50% to 90%, and 75% to 100%.
Data synthesis
We used the RevMan software package to perform a series of
meta-analyses for continuous and dichotomous outcome mea-
sures (RevMan 2012). We used a random-effects model to account
for the fact that participants did not come from a single underlying
population. We combined two studies of the therapeutic commu-
nity and aftercare in comparison to treatment as usual.
Subgroup analysis and investigation of heterogeneity
We had planned to conduct sensitivity analyses to assess the im-
pact of studies at high risk of bias compared with those at low or
unclear risk of bias. Because of the overall high risk of bias of the
included studies, this analysis was not possible.
Grading of evidence and 'Summary of findings' tables
We assessed the overall quality of the evidence for the following pri-
mary outcomes using the GRADE system: relapse, frequency of use,
extent of use, any adverse events, and dropout from treatment. The
GRADE Working Group developed a system for grading the quality
of evidence (Schunemann 2013); this system takes into account is-
sues related not only to internal validity but also to external validi-
ty, such as directness of results.
We have presented the main findings of the review in a 'Summary
of findings' table. This transparent and simple tabular format pro-
vides key information concerning quality of evidence, magnitude
of effect of the interventions examined, and sums of available data
for the main outcomes.
The GRADE system uses the following criteria for assigning grades
of evidence.
• High: we are very confident that the true effect lies close to that
of the estimate of the effect.
• Moderate: we are moderately confident in the effect estimate:
the true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different.
• Low: our confidence in the effect estimate is limited: the true ef-
fect may be substantially different from the estimate of the ef-
fect.
• Very low: we have very little confidence in the effect estimate:
the true effect is likely to be substantially different from the es-
timate of effect.
Grading is decreased for the following reasons.
• Serious (-1) or very serious (-2) study limitations for risk of bias.
• Serious (-1) or very serious (-2) inconsistency between study re-
sults.
• Some (-1) or major (-2) uncertainty about directness (correspon-
dence between the population, the intervention, or the out-
comes measured in the studies actually found and those under
consideration in our systematic review).
• Serious (-1) or very serious (-2) imprecision of the pooled esti-
mate.
• Publication bias strongly suspected (-1).
R E S U L T S
Description of studies
Results of the search
As shown in Figure 1, our update searches identified 9653 records.
We screened out 9424 references based on titles and abstracts. We
examined the remaining 229 records in full text and excluded 224
of them (see Characteristics of excluded studies). We included five
new trials,(Cullen 2012; Dakof 2015; Malouf 2017; McCarter 2016;
Sundell 2008), along with one follow-up study to an existing tri-
al within the review (Lanza 2014), and we included three ongoing
trials (Baldus 2011; Tinland 2013; VanDorn 2017), along with eight
studies from the previous review. The total number of included
studies is 13 (see Characteristics of included studies).
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Figure 1.   Study flow diagram.
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Included studies
Population
The 13 included trials randomised a total of 2606 participants and
were published between 1999 and 2017. Seven of the 13 trials
included adult drug-using offenders. Three studies investigated
the impact on interventions with adolescents and/or youth (Dakof
2015; McCarter 2016; Stein 2011). Two studies included females on-
ly (Johnson 2012; Sacks 2008). Three studies reported on juveniles
or youth involved in the criminal justice system (Dakof 2015; Mc-
Carter 2016; Stein 2011). Adult male offenders were the focus of
study populations in the remaining studies, with a mean age of 30
years. In all but two studies (Cullen 2012; McCarter 2016), most par-
ticipants were of white ethnic origin.
Mental health diagnoses varied across studies (see Table 1.
Settings
Eight studies were conducted in a secure setting (Johnson 2012;
Lanza 2014; Malouf 2017; Sacks 2004; Sacks 2008; Sacks 2011; Stein
2011; Wexler 1999), two studies were conducted in community set-
tings (Cosden 2003; Sundell 2008), and two studies were conducted
in court settings (Dakof 2015; McCarter 2016). One study was con-
ducted with a medium forensic secure hospital population in the
United Kingdom (Cullen 2012). Studies were published in the Unit-
ed States (n = 10/13; 76%), Spain (n = 1/13; 7.6%), the United King-
dom (n = 1/13; 7.6%), and Sweden (n = 1/13; 7.6%).
Duration of trials
Trial duration varied between three-month follow-up in Johnson
2012, Lanza 2014, Stein 2011, and Sundell 2008, and five-year fol-
low-up in Wexler 1999. Six-month follow-up was reported in Cosden
2003, Dakof 2015, and Sacks 2008. The remaining studies reported
on outcomes at 12, 24, and 36 months (Cosden 2003; Cullen 2012;
Dakof 2015; Malouf 2017; McCarter 2016; Sacks 2011; Sacks 2004).
Treatment duration was most intensive (e.g. lasting between three
and seven days per week) when a therapeutic community model
was employed for periods of up to 12, 18, and 24 months (e.g. Sacks
2004; Sacks 2008; Sacks 2011); typically all other treatment inter-
ventions lasted between four and six months (e.g. Cullen 2012; Lan-
za 2014). The shortest treatment intervention was delivered in a 90-
minute session followed by a 60-minute booster session upon re-
lease (Stein 2011).
Outcome measures
A total of 5 of 13 (38%) trials reported drug outcomes (Cullen 2012;
Johnson 2012; Lanza 2014; Stein 2011; Sundell 2008), 5 of 13 (38%)
reported crime outcomes (Dakof 2015; McCarter 2016; Sacks 2004;
Sacks 2011; Wexler 1999), and 3 of 13 (23%) reported both drug and
crime outcomes (Cosden 2003; Malouf 2017; Sacks 2008).
Interventions
Therapuetic interventions and aAercare
Four studies compared a therapeutic community (TC) intervention
with aftercare versus treatment as usual (Sacks 2004; Sacks 2011),
another intervention (Sacks 2008), or no intervention (Wexler
1999). Sacks 2004 compared a modified TC residential treatment
programme using a cognitive-behavioural curriculum to change
attitudes and lifestyles versus a programme of intensive psy-
chiatric services with medication, weekly individual therapy and
counselling, and specialised groups of cognitive-behavioural work,
anger management, therapy and education, domestic violence,
parenting, and weekly drug/alcohol therapy sessions.
Sacks 2008 evaluated a modified TC group with programme activi-
ties supplemented by peer-led activities on weekends in compari-
son to an intensive outpatient programme that consisted of an ed-
ucational programme on substance abuse treatment.
Sacks 2011 consisted of a re-entry residential TC programme where
participants worked in the community and saved money for inde-
pendent living. This was compared to participants who were re-
leased to a community corrections facility during the day; they
leC the facility to go to work, receive treatment, and report to pa-
role officers. This group engaged with brokering community-based
services and directly received support and counselling services. A
weekly relapse prevention group and daily medication monitor-
ing were provided. Psychiatric and substance abuse services were
provided by outside agencies (community parole officers helped
clients choose). The Wexler study compared a TC treatment pro-
gramme with aftercare in the community versus a waiting list con-
trol.
Mental health court
One study compared use of a mental health court and case man-
agement to treatment as usual (Cosden 2003). The mental health
treatment court (MHTC) consisted of case management and as-
sertive community treatment (ACT) provided via a case manage-
ment model. This model included weekly or bi-weekly court super-
vision and frequent contact with case managers, followed by treat-
ment as usual (if required), and compared this to treatment as usu-
al, which included traditional court proceedings and county men-
tal health services (Cosden 2003).
Motivational interviewing, mindfulness, and cognitive skills
Four studies compared motivational interviewing, mindfulness,
and cognitive skills to no intervention (Lanza 2014), another inter-
vention (Stein 2011), or treatment as usual (Cullen 2012; Malouf
2017). Stein 2011 was a manualised motivational intervention fo-
cused on empathy - not arguing and developing discrepancy; self-
efficacy; and personal choice, and compared this approach to a re-
laxation intervention that included progressive muscle relaxation,
use of guided imagery, and feedback on use of techniques.
Malouf 2017 used a manualised group intervention for jail inmates
nearing release into the community. The intervention incorporat-
ed and adapted elements from several mindfulness-based inter-
ventions (MBIs), including acceptance and commitment therapy,
mindfulness-based relapse prevention (MBRP), and dialectical be-
havioural therapy (DBT), and was compared to programmes that
were normally available within the prison (e.g. anger management
financial planning, health education).
Lanza 2014 used cognitive-behavioural therapy (CBT) to change
behaviour through cognitive restructuring and compared to ACT,
which aimed to construct an alternative context in which behaviour
aligned with one’s values is more likely to occur.
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Multi-systemic therapy including families
Two studies compared multi-systemic therapy including families
versus treatment as usual (in Sundell 2008) and another interven-
tion (in Dakof 2015). Sundell 2008 compared an intensive fami-
ly- and community-based treatment to support prosocial develop-
ment versus individual counselling, family therapy, addiction treat-
ment, and special education services.
Dakof 2015 compared an intervention that involved therapists who
worked individually with each family in four areas of treatment
(adolescent, parent, family, and community) versus adolescent
group therapy based on cognitive-behavioural therapy and moti-
vational interviewing.
Legal defence and social work
One study compared legal defence and wrap-around social work
to legal defence service only (McCarter 2016). The wrap-around ap-
proach provides a collaborative and co-ordinated response of ser-
vice providers that organises and streamlines service delivery. This
includes attending any team meeting with or on behalf of youth,
providing service referrals, and connecting families and guardians
to local providers for appropriate mental health, substance abuse,
and educational services and support. This was compared to pro-
vision of only legal defence service.
Interpersonal psychotherapy
One study compared interpersonal psychotherapy versus another
intervention (Johnson 2012). Study participants in the intervention
group received manualised group and individual sessions in prison
for treatment of substance misuse and mental health problems.
These approaches were compared to an attention-matched manu-
alised in-prison and post-release psychoeducation course on men-
tal health and drug problems.
Excluded studies
We excluded 224 full-text studies. (See Characteristics of excluded
studies for further details.) Reasons for exclusion were lack of crim-
inal justice involvement in referral to the intervention; lack of re-
porting of relevant drug or crime outcome measures, or both, at
pre- and post-intervention periods; and allocation of participants
to study groups that were not strictly randomised or did not contain
original trial data.
Risk of bias in included studies
Allocation
Randomisation
All 13 studies were described as randomised. Nine of the included
studies reported on how the randomisation sequence was generat-
ed and were judged as having low risk of bias (Cosden 2003; Dakof
2015; Johnson 2012; Lanza 2014; Malouf 2017; McCarter 2016; Sacks
2011; Stein 2011; Sundell 2008). The remaining four studies did not
report how the randomisation sequence of participants was gener-
ated (Cullen 2012; Sacks 2004; Sacks 2008; Wexler 1999).
Characteristics at baseline
Eight of the 13 studies were similar in terms of drug use at base-
line (Cullen 2012; Dakof 2015; Johnson 2012; McCarter 2016; Sacks
2008; Sacks 2011; Stein 2011; Wexler 1999); four studies were rated
unclear (Cosden 2003; Lanza 2014; Malouf 2017; Sundell 2008); and
one study showed comparable baseline differences (Sacks 2004).
For similarity on criminal justice measures, nine studies were rat-
ed as similar (Cosden 2003; Cullen 2012; Dakof 2015; Johnson 2012;
McCarter 2016; Sacks 2008; Sacks 2011; Sacks 2004; Wexler 1999),
and four were rated as unclear (Lanza 2014; Malouf 2017; Stein
2011; Sundell 2008).
Allocation concealment
Of the 13 studies, only two adequately reported that the allocation
process was concealed (Johnson 2012; Sundell 2008 ). The remain-
ing 11 (85%) studies were rated as unclear.
Blinding
We assessed risk of detection bias across subjective and objective
measures (see Appendix 12). We rated eight studies as having un-
clear risk (Cosden 2003; McCarter 2016; Sacks 2004; Sacks 2008;
Sacks 2011; Stein 2011; Sundell 2008; Wexler 1999); two studies as
having low risk (Cullen 2012; Lanza 2014); and the remaining three
studies as having high risk of bias.
Incomplete outcome data
Loss to follow-up was reported to a differing extent in the included
studies. We rated six studies as having low risk with limited attrition
noted (Johnson 2012; Lanza 2014; Sacks 2004; Stein 2011; Sundell
2008; Wexler 1999); three studies as having unclear risk (Dakof 2015;
Sacks 2008; Sacks 2011); and four studies as having high risk of bias
(Cosden 2003; Cullen 2012; Malouf 2017; McCarter 2016).
Selective reporting
We rated five of the thirteen trials as having unclear risk of bias (Mc-
Carter 2016; Sacks 2004; Stein 2011; Sundell 2008; Wexler 1999); six
studies as having low risk (Cosden 2003; Cullen 2012; Lanza 2014;
Malouf 2017; Sacks 2008; Sacks 2011), and two studies as having
high risk of bias (Dakof 2015; Johnson 2012).
See Figure 2 and Figure 3 for details.
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
 
Interventions for drug-using oenders with co-occurring mental health problems (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
25
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Eects of interventions
See: Summary of findings for the main comparison Therapeutic
community compared to treatment as usual for drug-using offend-
ers with co-occurring mental illness; Summary of findings 2 Thera-
peutic community and aftercare compared to cognitive behaviour-
al skills for drug using women offenders with co-occurring men-
tal illness; Summary of findings 3 Therapeutic community com-
pared to waiting list control for drug-using offenders with co-oc-
curring mental illness; Summary of findings 4 Mental health treat-
ment court with assertive case management model compared to
treatment as usual for drug-using offenders with co-occurring men-
tal illness; Summary of findings 5 Motivational interviewing/mind-
fulness and cognitive skills compared to relaxation training for
drug-using offenders with co-occurring mental illness; Summary
of findings 6 Motivational interviewing/mindfulness and cognitive
skills compared to waiting list control for drug-using offenders with
co-occurring mental illness; Summary of findings 7 Motivational
interviewing/mindfulness and cognitive skills compared to treat-
ment as usual for drug-using offenders with co-occurring mental
illness; Summary of findings 8 Multi-systemic therapy involving
family and juveniles compared to treatment as usual for drug-using
offenders with co-occurring mental illness; Summary of findings
9 Multi-systemic therapy involving family compared to group sub-
stance abuse therapy for drug-using adolescents with co-occurring
mental illness; Summary of findings 10 Interpersonal psychother-
apy compared to a psychoeducational intervention for drug-us-
ing offenders with co-occurring mental illness; Summary of find-
ings 11 Legal defence service and wrap-around social work services
compared to legal defence service only for drug-using offenders
with co-occurring mental illness
1. Therapeutic community and aAercare versus treatment as
usual
See Summary of findings for the main comparison.
Impact on self-reported drug use
This was not reported.
Impact on self-reported criminal activity
Sacks 2011 and Sacks 2004 were combined to show a significant re-
duction in the number of re-arrests (risk ratio (RR) 0.67, 95% confi-
dence interval (CI) 0.53 to 0.84) and re-incarcerations (RR 0.40, 95%
CI 0.24 to 0.67), with moderate-certainty evidence at 12-month fol-
low-up (266 participants; see Analysis 1.1).
2. Therapeutic community and aAercare versus cognitive-
behavioural skills for drug-using women
See Summary of findings 2.
Impact on self-reported drug use
Sacks 2008 showed no significant reduction in self-reported drug
use (RR 0.78, 95% CI 0.46 to 1.32), with low-certainty evidence at
six-month follow-up (314 participants; see Analysis 2.1).
Impact on self-reported criminal activity
Sacks 2008 showed no significant reduction in re-arrest for any type
of crime (RR 0.69, 95% CI 0.44 to 1.09), criminal activity (RR 0.74,
95% CI 0.52 to 1.05), or drug-related crime (RR 0.87, 95% CI 0.56 to
1.36), with low-certainty evidence at six-month follow-up (314 par-
ticipants; see Analysis 2.2, Analysis 2.3, and Analysis 2.4).
3. Therapeutic community versus waiting list control
See Summary of findings 3.
Impact on self-reported drug use
This was not reported.
Impact on self-reported criminal activity
Wexler 1999 showed a significant reduction (but a trend towards
favouring) return to prison in favour of the therapeutic community
intervention (RR 0.60, 95% CI 0.46 to 0.79), with moderate-certainty
evidence at 36-month follow-up (478 participants; see Analysis 3.1).
4. Mental health treatment court with assertive case
management model versus treatment as usual
See Summary of findings 4.
Impact on self-reported drug use
Cosden 2003 showed no significant reduction in Addiction Severity
Index (ASI)-self-reported drug use (mean difference (MD) 0.00, 95%
CI -0.03 to 0.03), with low-certainty evidence at 12-month follow-up
(235 participants; see Analysis 4.3).
Impact on self-reported criminal activity
Cosden 2003 showed no significant reduction in conviction for a
new crime (RR 1.05, 95% CI 0.90 to 1.22) or re-incarceration to jail
(RR 0.79, 95% CI 0.62 to 1.01), with low-certainty evidence at 12-
month follow-up (235 participants; see Analysis 4.1 and Analysis
4.2).
5. Motivational interviewing/mindfulness and cognitive skills
versus relaxation therapy
See Summary of findings 5.
Impact on self-reported drug use
Stein 2011 compared cognitive skills to a relaxation training inter-
vention for adolescents in prison with depressed mood. This study
measured marijuana use at three-month follow-up assessment us-
ing the Risks and Consequences Questionnaire (RCQ). Researchers
reported a main effect < .007, with participants in the motivation-
al interviewing group showing fewer problems than participants in
the relaxation training group. No further numerical information is
available (moderate-certainty of evidence; 181 participants).
Impact on self-reported criminal activity
This was not reported.
6. Motivational interviewing/mindfulness and cognitive skills
versus waiting list control
See Summary of findings 6.
Impact on self-reported drug use
Lanza 2014 reported no significant reduction in self-reported drug
use based on the ASI (MD -0.04, 95% CI -0.37 to 0.29) and abstinence
from drug use (RR 2.89, 95% CI 0.73 to 11.43), with low-certainty ev-
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idence at six months (31 participants; see Analysis 5.1 and Analysis
5.2).
Impact on self-reported criminal activity
Studies did not assess this outcome.
7. Motivational interviewing/mindfulness and cognitive skills
versus treatment as usual
See Summary of findings 7.
Impact on self-reported drug use
Malouf 2017 found no significant reduction in frequency of marijua-
na use (MD -1.05, 95% CI -2.39 to 0.29), with very low-certainty ev-
idence at three months post release (40 participants; see Analysis
6.1).
Cullen 2012 found no significant reduction in positive drug screens
(MD -0.7, 95% CI -3.5 to 2.1), with very low-certainty evidence at 12
months (84 participants; see Analysis 6.4).
Impact on self-reported criminal activity
Malouf 2017 found a significant reduction in frequency of re-arrest
(MD -0.66, 95% CI -1.31 to -0.01) but not in time to first arrest (MD
0.87, 95% CI -0.12 to 1.86), with very low-certainty evidence up to
36 months (40 participants; see Analysis 6.2 and Analysis 6.3).
8. Multi-systemic therapy (involving family) and juveniles
versus treatment as usual
See Summary of findings 8.
Impact on self-reported drug use
Sundell 2008 found no significant reduction in drug dependence
on the Drug Use Disorders Identification Test (DUDIT) score (MD
-0.22, 95% CI -2.51 to 2.07), with low-certainty evidence up to seven
months (156 participants; see Analysis 7.2).
Impact on self-reported criminal activity
Sundell 2008 found no significant reduction in arrests (RR 0.97, 95%
CI 0.70 to 1.36), with low-certainty evidence up to seven months
(158 participants; see Analysis 7.1).
9. Multi-systemic therapy (involving family) versus adolescent
group substance abuse therapy
See Summary of findings 9.
Impact on self-reported drug use
This was not reported.
Impact on self-reported criminal activity
Dakof 2015 reported no significant reduction in re-arrests (MD
-0.24, 95% CI -0.76 to 0.28), with low-certainty evidence up to 24
months (112 participants; see Analysis 8.1).
10. Interpersonal psychotherapy versus a psychoeducational
intervention
See Summary of findings 10.
Impact on self-reported drug use
Johnson 2012 reported no significant reduction in self-reported
drug use (RR 0.67, 95% CI 0.30 to 1.50), with very low-certainty evi-
dence up to three months (38 participants; see Analysis 9.1).
Impact on self-reported criminal activity
This was not reported.
11. Legal defence service and wrap-around social work
services versus legal defence service only
See Summary of findings 11.
Impact on self-reported drug use
This was not reported.
Impact on self-reported criminal activity
McCarter 2016 reported no significant reduction in the number of
new offences committed (RR 0.64, 95% CI 0.07 to 6.01), with very
low-certainty evidence up to 12 months (29 participants; Analysis
10.1).
D I S C U S S I O N
Summary of main results
This systematic review provides evidence from 13 trials involving
2606 participants and evaluating 11 different comparisons; one
pooled analysis was possible. Certainty of evidence was generally
low. Most interventions were delivered in prison-based (eight stud-
ies; 61%), court (two studies; 15%), community (two studies; 15%),
or medium secure hospital (one study; 8%) settings. Most studies
compared an intervention versus treatment as usual or another in-
tervention (11/13 studies; 84%).
The 11 different treatment comparisons were divided into:
• therapeutic community and aftercare versus treatment as usual
(Sacks 2004; Sacks 2011);
• therapeutic community and aftercare versus a cognitive-behav-
ioural skills course (Sacks 2008); and
• therapeutic community and aftercare versus a waiting list con-
trol (Wexler 1999).
Two studies comparing therapeutic community interventions re-
ported a significant reduction in subsequent re-incarceration and
criminal activity compared to treatment as usual (Sacks 2004;
Sacks 2011), with moderate-certainty evidence. Sacks 2008 adapt-
ed a therapeutic community treatment for women offenders com-
pared to a cognitive-behavioural skills course. This study compared
women assigned to therapeutic community treatment or standard
treatment versus a cognitive-behavioural recovery and relapse pre-
vention curriculum, referred to in the system as the 'intensive out-
patient programme' (Sacks 2008), with low-certainty evidence. At
six months, researchers found that both groups improved signifi-
cantly on variables of mental health, substance use, criminal be-
haviour, and HIV risk. Study authors noted that further exploration
of each model for different offender groups is required to permit
more precise utility of each model. They concluded that these pre-
liminary findings suggest the importance of providing gender-spe-
cific sensitive and comprehensive approaches within the correc-
tional system to respond to the complex substance abuse needs of
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female offenders (Sacks 2008). Therapeutic community treatment
was found to be more beneficial than cognitive-behavioural thera-
py, lengthening time spent in the community before subsequent re-
incarceration (Sacks 2008). This finding partially supports previous
research suggesting that the combination of therapeutic communi-
ty treatment and aftercare release seems to produce the most con-
sistent and successful results among offenders who do not have co-
occurring mental health problems (Mitchell 2012a). Although this
is not addressed within this review, clients who remained in treat-
ment for the longest period appeared to benefit the most (Sacks
2004). These differences seem to be borne out for up to 36 months
when compared to people who received nothing, suggesting that
over time, the impact of the intervention eventually became dissi-
pated (Wexler 1999), with moderate-certainty evidence. Only one
of the four studies reported on outcomes of drug use (in women)
and found no reductions following the intervention in compari-
son to attending a cognitive skills course (Sacks 2008). We do not
know whether drug use is reduced in men with co-occurring mental
health problems.
Mental health treatment court (MHTC) and use of an assertive
case management model versus treatment as usual
People under the care of the criminal justice system in both groups
showed improvement across a range of outcomes in life satisfac-
tion, a decrease in distress levels, and improvement in independent
living. Overall, the pattern of criminal activity suggested that both
groups spent time in jail but for different reasons. The individual
under the care of the MHTC was more likely to be 'booked' for a
crime and not convicted and to have more convictions due to pro-
bation violation in comparison to individuals who had received on-
ly treatment as usual. Those people receiving treatment as usual
were more likely to be convicted of a new offence (Cosden 2003),
with low-certainty evidence.
Motivational interviewing/mindfulness and cognitive skills
versus a waiting list control; motivational interviewing/
mindfulness and cognitive skills versus relaxation training;
motivational interviewing/mindfulness and cognitive skills
versus treatment as usual
See Cullen 2012, Lanza 2014, Malouf 2017, and Stein 2011.
Four studies of motivational interviewing/mindfulness and cogni-
tive skills compared to a waiting list control, relaxation training,
and treatment as usual reported moderate- to very low-certainty
evidence. No significant differences were noted across these stud-
ies, suggesting that use of such skills may not reduce subsequent
drug use and/or criminal activity in comparison to any of the alter-
natives. In addition, one of the four studies was a pilot randomised
controlled trial (RCT) of motivational interviewing versus treatment
as usual, which suggests that larger studies are required to support
any future findings. Use of self-reported measures often contami-
nated by social desirability bias means that confidence in these re-
sults may be limited (moderate-certainty evidence; Malouf 2017).
Multi-systemic therapy (MST) involving families versus
treatment as usual; MST involving families versus group-based
substance abuse therapy
Two studies of multi-systemic therapy for juveniles included fam-
ilies and compared treatment as usual or an alternative group-
based substance abuse therapy (Dakof 2015; Sundell 2008). Find-
ings show that MST did not support short-term effectiveness rela-
tive to services usually available for conduct disordered youths in
Sweden (Sundell 2008). This outcome is contrary to other work con-
ducted in the United States and Norway but similar to work per-
formed in Canada (Cunningham 2002). Sundell 2008 highlighted
the importance of measuring and monitoring fidelity during trans-
portation and delivery of interventions to other settings and dif-
ferent countries worldwide; the importance of the impact of social
context should not be underestimated (low-certainty evidence).
Interpersonal psychotherapy versus psychoeducational
intervention
One pilot study of interpersonal psychotherapy in comparison to a
psychoeducational intervention showed no significant reduction in
subsequent drug use. However, these results should be interpreted
with caution, given the small sample and the short follow-up period
(very low-certainty evidence; Johnson 2012).
Legal defence work and wrap-around social services versus
legal defence work only
One pilot study of legal defence work and wrap-around social ser-
vices in comparison to legal defence work with juveniles did not
reveal any significant reduction in subsequent return to prison in
the 12-month follow-up period. Study authors argue that holis-
tic representation services can help to provide protective factors
that might strengthen underlying risks and needs of young peo-
ple, which might contribute to additional court involvement and/
or re-offending in the future (very low-certainty evidence; McCarter
2016).
Succesful treatment elements and dealing with complex co-
occurring problems
In terms of addressing some of the complex issues of individuals
with mental health problems and co-occurring substance abuse,
the evidence from this systematic review provides sparse informa-
tion.
Several successful treatment elements were reported throughout
these trials, and several key themes can be identified.
First, we noted that the issue of treatment engagement was impor-
tant. In the mental health court trial, informal support from fam-
ily and friends encouraged the engagement of clients within the
community to longer-term gain, but more research is required to
assess whether interventions that empower families can enhance
and sustain outcomes longer than non-family-based interventions
(Cosden 2003; Dakof 2015).
Second, programmes that were specifically adapted to the needs
of mental health clients tended to include a cognitive-behaviour-
al curriculum that emphasised criminal thinking and behaviour
alongside psychoeducational classes. The purpose of combining
these two types of mechanisms is to enhance an individual's ability
to recognise and understand his/her substance misuse and mental
health problems in greater detail (Sacks 2004).
Third, the longer an individual is engaged in treatment, the better
is the outcome(s) (Wexler 1999).
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Overall completeness and applicability of evidence
General applicability
Applicability of the evidence is hindered in general by the range of
trials covering various different treatment options, making it inap-
propriate to pool study results. Most trials were conducted within
the US judicial system; therefore, they are limited in their generalis-
ability to criminal justice systems outside the United States. Three
trials conducted in Spain (Lanza 2014), the United Kingdom (Cullen
2012), and Sweden provide a European perspective but with mod-
erate-certainty evidence (Sundell 2008). As a result, study findings
must be interpreted with caution.
Mental health information
Although this review specifically sought to identify studies includ-
ing participants with co-occurring mental health problems, study
descriptions of mental ill health varied (see Table 1). Cosden 2003
used a psychiatrist or a psychologist to conduct a clinical interview
to determine a mental health diagnosis alongside substance mis-
use. This resulted in a mental health court sample of individuals di-
agnosed with various mental health problems, including mood dis-
order, schizophrenia, bipolar disorder, and dual diagnosis. Other
papers referred to use of Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition (DSM-IV) diagnostic criteria, akin to the
Youth Self-Report measure (Dakof 2015; McCarter 2016; Sacks 2011;
Sundell 2008), but subsequently provided little information with re-
gards to individual mental health needs. Demographic information
in Sacks 2004 revealed other aspects of mental health prognosis,
including lifetime mental health treatment, lifetime patient care,
and prescribed medication.
The Wexler 1999 series of studies reported a range of diagnoses,
including antisocial personality disorder, phobias, post-traumatic
stress disorder, depression, dysthymia, and attention deficit disor-
der, but did not describe how these diagnoses were confirmed or
assessed within the population.
Six of the 13 trials reported on change in mental health well-be-
ing. Three trials reported on use of the Beck Depression Inven-
tory, the Global Severity Index, and the Posttraumatic Diagnostic
Scale (Sacks 2004; Sacks 2008; Sacks 2011). Another study reported
on depression but used the Hamilton Rating Scale for Depression
(Johnson 2012). Four studies reported the presence of mood disor-
der alongside schizophrenia, general anxiety disorder, and/or anti-
social personality disorder (Cosden 2003; Cullen 2012; Lanza 2014;
Malouf 2017). Four studies discussed differential effects of treat-
ment on the severity of depression (Cosden 2003; Johnson 2012;
McCarter 2016; Stein 2011). Cosden 2003 noted that further under-
standing of how to help clients with serious mental health prob-
lems through different levels of treatment is needed. Johnson 2012
noted that participants undergoing interpersonal psychotherapy
had significantly reduced levels of depression and substance mis-
use over attention-matched controls. Study authors noted that the
intensity of treatment delivered once the individual is released in-
to the community is key to maintaining good outcomes. However,
they go on to state that people under the care of the criminal jus-
tice system often experience delays in treatment and service provi-
sion on release, and they suggest that alternative services such as
phone treatment might be helpful in providing more intensive and
useful post-release treatment in times of crisis.
Quality of the evidence
We rated eight of 13 (62%) studies as having unclear risk of bias in
more than four of eight domains. The main limiting factor was lack
of reporting evidence, which prevented review authors from mak-
ing a clear judgement on bias. Given that the imprecision of report-
ing lowers the quality of evidence, further research is very likely to
have an important impact on our confidence in the estimate of ef-
fect and is likely to change the estimate. In addition, several specif-
ic limitations related to study design (and leading to problems of
selection bias) were described, and sample sizes were small. Stein
2011 and Cullen 2012 were noted as being relatively underpowered.
Replication of these studies is required to enhance the generalis-
ability and external validity of study findings.
Similar modest sample sizes were reported, with some trials re-
ferred to as pilot studies (e.g. Malouf 2017; McCarter 2016). Sacks
2011 and Cosden 2003 suggest that larger samples should be used
to provide a more precise estimate of effect. Small sample sizes lim-
it the generalisability of the sample population to other settings,
and few studies collected longitudinal data sufficient to support
the ongoing use of such schemes without additional larger trials
commissioned (Cullen 2012; Dakof 2015; McCarter 2016). Cosden
2003 also reported on the possibility of outcome bias, as the inter-
viewer was not blind to the outcome condition of the participant
nor to loss to follow-up (25% of the study sample were lost to fol-
low-up) at 12 months.
Another possible selection bias concern in the series of Wexler stud-
ies was that participants were randomly assigned to prison ther-
apeutic community treatment and regular prison conditions but
not to aftercare (Prendergast 2003; Prendergast 2004; Wexler 1999).
Study authors noted that possible differences in personal motiva-
tion may account for some of the positive outcomes associated
with participants' continued support for aftercare services. Subse-
quently, these participants were noted as having the highest 'readi-
ness scores', which suggests that motivation creates an important
consideration for client selection (Wexler 1999). Cullen 2012 report-
ed on the use of randomisation within sites, which may have led
to contamination across treatment groups, and the likelihood that
further selection bias might have arisen from the fact that declining
patients were more unwell and/or antisocial, and that these factors
might influence treatment outcomes (Cullen 2012).
Overall we judged the certainty of evidence as moderate to very low
for all included interventions.
Potential biases in the review process
Besides the limitations already discussed, the search method was
limited to databases that could be accessed via the University of
York, and extensive website searches were not conducted. We did
not search specific trial registers. As a result, some literature may
have been omitted from this updated version.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review provides moderate- to very low-certainty evidence sug-
gesting that use of therapeutic interventions might reduce subse-
quent criminal activity compared to control interventions such as
treatment as usual, an alternative intervention, or nothing. Men-
tal health treatment courts may reduce the number of subsequent
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new crimes committed in comparison to treatment as usual. We
do not have sufficient evidence to support whether these inter-
ventions are effective for both men and women involved in the
criminal justice system, and evidence is insufficient to permit any
judgements about differential effectiveness among different eth-
nic groups. Longer or more intensive interventions appear to have
some effect on improving outcomes but perhaps only up until a
particular time point. A further challenge in this field is the very
wide range of outcome measures, which are reported over greatly
varying periods of time. We identified too few trials reporting many
of these outcome measures to provide sufficient statistical power
to detect potentially small effects.
Implications for research
We have identified several research implications.
• Good quality research is required to evaluate the effectiveness
of interventions for offenders with substance misuse problems
and co-occurring mental health problems. Of particular inter-
est are the extended long-term effects of aftercare and the lev-
el of contact required with services in the community. Further
research to explore the intensity of different community treat-
ment alternatives following release may help to unravel this
process.
• Better descriptions of participants' mental health problems and
more detailed information about mental health diagnoses are
required to enable the transferability of information to clinical
practice. Such information could also facilitate the use of men-
tal health diagnoses as a moderator within analysis of these out-
comes.
• Trial interventions specifically focusing on females and adoles-
cents are required. In the current review, two studies focused
only on females, and three studies reported on outcomes with
youth involved in the criminal justice system.
• Little is known about the interaction between mental health
problems, individual personal characteristics, and positive out-
comes related to treatment success. In terms of depression,
Stein 2011 attempted to explore some of the differences be-
tween participants with few and with many depressive symp-
toms. Future studies should consider an analysis of existing da-
ta sets that might reveal which individuals with which mental
health diagnoses fare better than others. This would reveal who
might potentially benefit most from treatment and would en-
able appropriate targeting of resources.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 235 adults
Age not reported
50.2% male
70.6% European American
Drug use not reported
Alcohol use not reported
100% psychiatric history
Eligibility criteria: adults charged with a crime or misdemeanour who were booked into county jail,
had at least 1 prior booking, were diagnosed with a serious and pervasive mental illness, and were res-
idents of the county involved. Pre-plea participants were required to have no previous offences involv-
ing violence; post-adjudication participants with prior violence were eligible if they were considered to
no longer pose a threat
Interventions Court-based sentencing and case management intervention vs treatment as usual
Experimental intervention
Psychosocial intervention: mental health treatment court (MHTC) consisting of case management and
assertive community treatment (ACT) based on a case management model: weekly or bi-weekly court
supervision and frequent contact with case managers, duration 18 months, followed by treatment as
usual if required (n = 137)
Setting: community
Length of treatment: 18 months
Length of follow-up: 6 months and 12 months
Cosden 2003 
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Control: treatment as usual: traditional court proceedings and county mental health services as usual
for at least 18 months, which was less intensive than the intervention (n = 98)
Setting: community
Length of treatment: 18 months
Length of follow-up: 6 months and 12 months
Outcomes Drug use (Addiction Severity Index, self-report) during the last month at 12 months' follow-up
Re-arrests
Notes Funding: this research was sponsored by a grant from the California State Board of Corrections, the
Mentally Ill Offender Crime Reduction Grant Program
Contract/grant sponsor: California State Board of Corrections
Conflict of interest: no declaration of interest reported by study authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk Insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk Insufficient information to permit judgement
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 25% of the initial population could not be located at the end of 12 months
Selective reporting (re-
porting bias)
Low risk All study outcomes listed and reported in the paper; no evidence of a trial pro-
tocol
Cosden 2003  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 84 adults
Average age: 35 years (SD 11.4)
100% male
52% African American
Cullen 2012 
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100% psychiatric history
Eligibility criteria: (a) a primary clinical diagnosis of psychotic disorder (schizophrenia, schizoaffec-
tive disorder, bipolar disorder, or other psychotic disorder); (b) history of violence; (c) not having par-
ticipated in R&R or a similar programme previously; (d) not actively psychotic (score of 4 on each of the
Positive and Negative Symptom Scale P items (PANSS; Kay, Opler, & Fiszbein, 2000); (e) absence of sig-
nificant cognitive impairments (i.e. IQ70 or impairments likely to lead to inability to cope with the de-
mands of the group); and (f) proficiency in English language sufficient to allow participation in the pro-
gramme as judged by the treating team. Patients with comorbid personality or substance use disorders
were not excluded
Interventions Reasoning and rehabilitation vs treatment as usual
Experimental intervention: psychosocial intervention: Reasoning and Rehabilitation (R&R) is a high-
ly structured, manualised programme targeting social problem-solving skills and thinking styles. This
programme is delivered over a minimum of 36 two-hour sessions and includes 8 core modules: prob-
lem-solving, assertiveness skills, social skills, negotiation skills, creative thinking, emotion manage-
ment, values reasoning, and critical reasoning. The programme was delivered by experienced sta- who
had received training during intensive 5-day workshops provided by the programme authors. Sessions
were held twice or three times weekly (5 to 8 patients per group). Unit sta- were given the flexibility to
deliver the original R&R programme or the revised programme (n = 44)
Setting: medium secure forensic hospital
Length of treatment: 36 two-hour sessions, 2 to 3 times per week. Participants attending a minimum
of 30 sessions were considered 'completers'
Length of follow-up: 12 months post intervention
Control: treatment as usual; none of the sites provided any other interventions that were aimed at re-
ducing violent or antisocial behavior throughout the trial (n = 40)
Setting: medium secure forensic hospital
Length of treatment: not reported
Length of follow-up: 12 months post intervention
Outcomes Urine drug screen for substance abuse
Notes Funding: financial support provided by the NHS National Research and Development Programme on
Forensic Mental Health Science, United Kingdom
Conflict of interest: not reported
Country: UK
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method used for random sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Method used for concealed allocation not reported
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
High risk "Researchers who conducted assessments were not blinded to allocation
status, as this information was often revealed in clinical notes or by patients
themselves"
Cullen 2012  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
objective outcomes
High risk "Researchers who conducted assessments were not blinded to allocation
status, as this information was often revealed in clinical notes or by patients
themselves"
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Although > 10% had missing data in both groups, 50% of the R&R group did
not complete treatment
Selective reporting (re-
porting bias)
Low risk Outcomes were represented in the paper; study authors specified primary and
secondary outcomes and listed all outcomes in the analyses
Cullen 2012  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 112 juveniles
100 (89%) male
Mean age (SD): not reported (age range reported as between 13 and 18 years)
Eligibility criteria: participants were (a) between the ages of 13 and 18; (b) diagnosed with substance
abuse or dependence based on a structured interview; (c) not actively suicidal, demonstrating psychot-
ic symptoms, or diagnosed with pervasive developmental disorder or mental retardation; (d) not cur-
rently charged for sale of drugs, weapons, or violent offences, or sexual battery; and (e) after consulta-
tion with their attorney, voluntarily enrolled in drug court
Interventions Multi-dimensional family therapy (MDFT) vs adolescent group-based treatment (AGT)
Experimental Intervention: MDFT family-based treatment: therapists work individually with each
family. Therapists work simultaneously in 4 interdependent treatment domains - adolescent, parent,
family, and community. At various points throughout treatment, therapists meet alone with the adoles-
cent, alone with the parent(s), or conjointly with the adolescent and parent(s), depending on the treat-
ment domain and the specific problem being addressed (n = 55)
Setting: juvenile drug court (JDC) sessions conducted in clinic and at home
Length of treatment: 4 to 6 months - with 2 sessions per week (average of 9.4 hours per month)
Length of follow-up: 6, 12, 18, and up to 24 months after baseline
Control: AGT was a manual-guided intervention based on cognitive–behavioural therapy and moti-
vational interviewing. Features and format were guided by research-supported principles and proce-
dures and combine education, skills training, and social support (Center for Substance Abuse Treat-
ment (CSAT)). Each session was structured, beginning with goal-setting/self-monitoring of goal attain-
ment, and followed by didactic/experiential activities, group processing/reflection, and closure. One
therapist led each session, with between 4 and 6 male and female adolescents participating. Groups
were "open" (vs "closed") in that new members were admitted on a rolling basis (n = 57)
Setting: juvenile drug court (JDC) sessions conducted in clinic
Length of treatment: 4 to 6 months - with 3 sessions per week (average of 10.56 hours per month)
Length of follow-up: 6, 12, 18, and up to 24 months after baseline
Outcomes Drug consumption
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Number of arrests
Notes Funding: the work reported was supported by the National Institute on Drug Abuse, Grant R01 DA
017478
Conflict of Interest: 2 study authors received financial compensation for their role as consultants and
members of the Board of Directors of MDFT International. One study author received financial compen-
sation for his role of Director on the MDFT Board
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Urn randomisation procedure to ensure equivalence
Allocation concealment
(selection bias)
Unclear risk Method used for allocating randomised participants to treatment groups not
reported
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Low risk Efforts were made to keep assessors unaware of study hypotheses and treat-
ment assignments
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Low risk Efforts were made to keep assessors unaware of study hypotheses and treat-
ment assignments
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Study authors report that an intent-to-treat analysis was used and provide
numbers withdrawing by group in a flow chart. However, statistical methods
used for handling missing data are not reported
Selective reporting (re-
porting bias)
High risk Not all outcomes are reported in the results. Two outcomes are reported in the
methods section of the paper: graduation from drug court, and length of time
on treatment; these are not included in the protocol
Dakof 2015  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 38 adults
Average age: 35 years (SD 9.2)
100% female
18% Hispanic, 18% African American
58% cocaine dependence, 24% opiate dependence, 21% marijuana dependence, 21% sedative/hyp-
notic dependence
58% alcohol dependence
100% psychiatric history
Johnson 2012 
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Criteria used for mental health diagnoses: "MDD as determined by the Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I; First et al., 1996a) after at least 4 weeks of abstinence and prison sub-
stance use treatment"
Description of mental health problem: major depressive disorder
Eligibility criteria: primary major depressive disorder as determined by the Structured Clinical Inter-
view for DSM-IV Axis I Disorders after at least 4 weeks of abstinence and prison substance use treat-
ment, minimum 17-item Hamilton Depression Scale score of 18, substance use disorder 1 month before
incarceration as determined by the SCID, 10 to 24 weeks away from prison release. Women with bipolar
disorder and psychotic disorder were excluded
Interventions Interpersonal psychotherapy vs psychoeducation attention-matched control
Experimental Intervention
Participants received manualised group and individual sessions in prison for treatment of substance
misuse and mental health problems. Participants in both conditions also received 6 weekly post-re-
lease individual sessions to help maintain gains and address crises as they transitioned to the commu-
nity. Session length varied between 60 and 75 minutes because of time taken to assemble women with-
in the facilities, occasional early prison counts, and other facility logistics. In-prison treatment was con-
densed into 2 months because many incarcerated women serve short sentences (30, 60, 90, 180 days)
(n = 19)
Setting: prison
Length of treatment: 60 to 75 minutes, 3 times a week for 8 weeks, plus pre/mid and post-group indi-
vidual sessions and 6 weekly post-release individual sessions to support transition into the community
Length of follow-up: end of treatment at 8 weeks
Control: participants received attention-matched manualised in-prison and post-release psychoedu-
cation, which is described as co-occurring mental health and substance use disorders (PSYCHOED). The
psychoeducation condition was adapted from a class on co-occurring disorders for prisoners that had
been used at the women’s facilities in the past but was not being used at the time of the study. It was
designed to be credible and engaging without focusing on the theorised active ingredients of interper-
sonal psychotherapy (e.g. focus on social support, relationships, life changes, analysis of communica-
tion, exploration of emotions). The stated purpose of PSYCHOED was to help women become informed
and to empower consumers of mental health treatment services. The 24 in-prison sessions focused on
the meaning of dual diagnosis, women’s experience with dual diagnosis, major depression, bipolar dis-
order, each of the anxiety disorders, post-traumatic stress disorder, personality disorders, psychotic
disorders, eating disorders, and self-care. Sessions for each disorder described symptoms (including
relevant self-report tests), interactions between the disorder and substance use, effects of the disorder
on women in prison (including film clips and written stories), and disorder-specific medication and psy-
chosocial treatment options. When a woman in the group had symptoms of a disorder, the group dis-
cussed her treatment options and preferences.
The 6 post-release sessions focused on women’s symptoms and connection with various mental health
and substance use treatment options in the community. Study treatments took place in addition to
prison treatment as usual. Treatment as usual consisted of prison residential or day treatment for sub-
stance use disorder (typically 16 to 30 hours per week) for all participants and prison mental health
treatment as usual for most participants (n = 19)
Setting: prison
Length of treatment: 60 to 75 minutes, 3 times a week for 8 weeks, plus pre/mid and post-group indi-
vidual sessions and 6 weekly post-release individual sessions to support transition into the community
Length of follow-up: end of treatment at 8 weeks
Outcomes Relapse defined as using drugs on at least 10% of non-incarcerated days or any positive breath test/
urine drug screen
Johnson 2012  (Continued)
Interventions for drug-using oenders with co-occurring mental health problems (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
50
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Notes Funding: work supported by US National Institute of Drug Abuse
Conflicts of interest: no declarations of interest were noted by study authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Wave randomisation used with at least 8 weeks between allocations to avoid
contamination across prison wings
Allocation concealment
(selection bias)
Low risk Random sequence generated by person independent of rest of study. Alloca-
tion adequately concealed from principal investigator and research assistants.
An independent individual concealed the assignment of each wave before the
study started. After the intake assessment was complete, the principal investi-
gator unsealed the waves treatment assignment
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Low risk Adequate blinding throughout study. Research assistants who conducted fol-
low-up assessment at 3 months after prison release were kept blind to the
condition
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Low risk Adequate blinding throughout the study. Research assistants who conducted
follow-up assessment at 3 months after prison release were kept blind to the
condition
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk  
No loss to follow-up; intention-to-treat analysis
Selective reporting (re-
porting bias)
High risk Did not report on SCID-I/SCID-II, Trauma History Questionnaire, or Timeline
Followback
Johnson 2012  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 50 adults
Average age: overall mean 33.2 (SD 7.2) (range 21 to 49)
CBT 35.2 (mean); ACT 31.1 (mean); control 33.1 (mean)
100% female
NR % white
% drug users: CBT 100%, ACT 83.3%, control 100%
% alcohol users: CBT 0%, ACT 16.7%, control 100%
% psychiatric history: 86% had at least 1 mental disorder
Eligibility criteria: met diagnostic criteria for current substance use disorder; serving sentence longer
than 6 months
Lanza 2014 
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Interventions Cognitive-behavioural therapy vs acceptance commitment therapy
Experimental Intervention one: cognitive-behavioural therapy (CBT) was used to change behaviour
through cognitive restructuring, whereby therapist works with offender to identify thoughts that cause
distress and uses cognitive and behavioural therapy to alter resulting behaviour. The main outcome of
the CBT intervention was increased abstinence from drug use; this was measured an corroborated by
urine analysis testing (n = 19)
Setting: prison
Length of treatment: 16 weekly group sessions lasting 90 minutes each
Length of follow-up: 6, 12, 18 months
Experimental Intervention two: acceptance commitment therapy (ACT) seeks to undermine the grip
of the literal verbal content of cognition that provokes avoidance behaviour and constructs an alter-
native context in which behaviour aligned with one’s values is more likely to occur. Sessions involve
both experiential and didactic learning to enable clients to experience and understand the size key
ACT processes. ACT helps offenders to respond to previously avoided events in new ways and uses val-
idation and empowerment. ACT was aimed at increasing substance use abstinence within the prison
population. After treatment offenders were assessed by the therapist, follow-up was conducted at 6
months (n = 18)
Setting: prison
Length of treatment: 16 weekly group sessions lasting 90 minutes each
Length of follow-up: 6, 12, 18 months
Control: received a mental health assessment at the same time as experimental groups. After 6-month
follow-up, they received treatment. Offenders received a re-educational programme for inmates during
incarceration (n = 13)
Setting: prison
Length of treatment: 16 weekly group sessions lasting 90 minutes each
Length of follow-up: 6, 12, 18 months
Outcomes Abstinence from drug use, corroborated by urinalysis
Percentage of abstinence
Notes Funding: work supported by Trust for the Promotion of Scientific Applied Research and Technology, in
Asturias, Spain
Conflict of Interest: no conflict of interest reported by study authors
Country: Spain
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Use of random numbers table noted
Allocation concealment
(selection bias)
Unclear risk No information reported
Blinding of outcome as-
sessment (detection bias) 
Low risk Urinalysis was used to corroborate self-reported abstinence
Lanza 2014  (Continued)
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subjective outcomes
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Low risk The clinician who conducted baseline assessments was also in charge of ad-
ministering the measures
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Similiar loss to follow-up across all 3 groups; a total of 9/50 lost (n = 4 for ACT, n
= 3 for CBT, n = 2 for control)
Selective reporting (re-
porting bias)
Low risk Protocol measures and information reported in the methods section of the pa-
per were comparable
Lanza 2014  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 40 adults
Average age: overall mean 37.2 (15.7)
Ethinicity not reported
% drug users: not reported
% alcohol users: not reported
% psychiatric history: REVAMP group 10.8% and TAU group 16.4% diagnosed at time one
Eligibility criteria: participants were 40 adult males incarcerated at a suburban jail in the mid-Atlantic
region of the USA. Inclusion criteria were assignment to the jail’s general population (i.e. not solitary
confinement), language proficiency in English, post-sentencing status, and a release date that would
allow adequate time for study participation. The group does contain those with a borderline personali-
ty disorder. No details are provided about how the sample was diagnosed
Interventions The Re-entry Values and Mindfulness Program (REVAMP) vs treatment as usual
Experimental intervention: the Re-entry Values and Mindfulness Program (REVAMP) is a manualised
group intervention for jail inmates nearing release into the community. It incorporates and adapts el-
ements from several mindfulness-based interventions (MBIs), including acceptance and commitment
therapy, mindfulness-based relapse prevention (MBRP), and dialectical behavioural therapy (DBT). RE-
VAMP begins with a focus on personal values identification to reduce defensiveness and increase mo-
tivation for treatment. Next, it uses a variety of exercises to reduce experiential avoidance and thereby
alleviate psychological suffering. These exercises include metaphors from ACT, distress tolerance skills
from DBT, and mindfulness meditation practices from MBRP. Treatment closes with return to a focus
on valued living, and participants are engaged in values clarification and goal identification exercises.
Throughout REVAMP, mindfulness meditation practice is encouraged through centring exercises at the
beginning and end of sessions, in addition to mindfulness meditation homework assignments (n = 21)
Setting: jail
Length of treatment: 2 times per week for 90 minutes for a total of 4 weeks
Length of follow-up: up to 3 years post release
Control: treatment as usual: included programmes that were normally available within the prison such
as anger management, financial planning, health education, GED preparation, religious services, sub-
stance abuse treatment, employability skills, and computer skills (n = 19)
Malouf 2017 
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Setting: jail
Length of treatment: not reported
Length of follow-up: up to 3 years post release
Outcomes Arrest frequency 3 years post release
Time to first arrest/offence 3 years post release
Frequency of marijuana use 3 months post release
Notes Funding: grant from the Center for Consciousness and Transformation (CCT) at George Mason Universi-
ty; 2 grants from the National Institute on Drug Abuse (NIDA) (#R01 DA14694 and #F31DA029397)
Conflict of interest: not reported
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Using a computerised random number generator
Allocation concealment
(selection bias)
Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Low risk All data were collected by trained research assistants who were blind to treat-
ment conditions
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Low risk All data were collected by trained research assistants who were blind to treat-
ment conditions
Incomplete outcome data
(attrition bias) 
All outcomes
High risk At follow-up, over 50% of the group had been lost to follow-up in the interven-
tion and treatment as usual arms. Reduction from n = 21 to n = 11 in the inter-
vention arm. Less loss to follow-up was shown in the treatment as usual group,
which was reduced from n = 19 to n = 13. Study authors do not mention how
they treated missing data in their analysis plan
Selective reporting (re-
porting bias)
Low risk Measures listed in the methods section of the paper
Malouf 2017  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 51 juveniles
Average age: overall mean 14.5 years
Ethinicity: 70% African American
% drug users:not reported
McCarter 2016 
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% alcohol users:not reported
% psychiatric history:not reported
Eligibility criteria: first-time offenders, ages 11 to 16, with assignment to an agency attorney. Exclu-
sion criteria were prior offences or a diversion contract, current mental health commitments, undisci-
plined designation, or limited English proficiency
Interventions Family wrap-around forensic social work services and existing legal defence service vs treatment as
usual comparison group
Experimental intervention: the wrap-around approach provides a collaborative and co-ordinated
response of service providers who organise and streamline service delivery. This includes attending
any team meeting with or on behalf of youth, providing service referrals, and connecting families and
guardians to local providers for appropriate mental health, substance abuse, and educational services
and support. When needed, they also arrange for physical health services at the local clinic that served
the adolescents' medical home (n = 22)
Setting: court and community
Length of treatment: not reported
Length of follow-up: 6 months after baseline and up to 12 months during the study
Control: received only legal defence service (n = 25)
Setting: court and community
Length of treatment: not reported
Length of follow-up: 6 months after baseline and up to 12 months during the study
Outcomes Recidivism
Notes Funding: supported in part by a Faculty Research Grant at the University of North Carolina Charlotte
Conflict of interest: not reported
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Individuals were assigned case numbers via a random number generator
Allocation concealment
(selection bias)
Unclear risk Insufficient information was provided
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Study authors describe intention-to-treat analysis. However, there is a signifi-
cant imbalance between missing data in the intervention and control groups,
with attrition rates of less than 10% and greater than 70%, respectively. Out-
McCarter 2016  (Continued)
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come data were reported for completers only, and 18/25 (72%) withdrew from
the control group
Selective reporting (re-
porting bias)
Unclear risk A study protocol is not reported to check for selective reporting. Prespecified
outcomes are reported, although without much detail. It is not clear where
"number of new offences" was stated beforehand
McCarter 2016  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 236 adults
Mean age 34.3 years (SD 8.8)
100% male
49% white
100% drug-using
32% alcohol-using
100% psychiatric history
Eligibility criteria: prisoners who had both a serious mental disorder and a substance use disorder
Interventions Secure establishment-based therapeutic community vs treatment as usual
Experimental intervention: the Personal Reflections initiative is a modified TC residential treat-
ment programme that uses a cognitive-behavioural curriculum within a foundation of TC principles to
change attitudes and lifestyles in 3 critical areas: substance abuse, mental illness, and criminal thinking
and behaviour. The intervention group received a mixture of psychoeducational classes, cognitive-be-
havioural methods, medication, and group therapy. Aftercare included mental health counselling,
medication and psychiatric services, and basic skills (n = 142)
Setting: prison
Length of treatment: 5 days per week for 4 to 5 hours per day for up to 12 months. Voluntary aftercare
following the TC intervention included attendance for between 3 and 7 days per week for 3 to 5 hours
per day for up to 6 months
Length of follow-up: 12 months post prison release
Control: received intensive psychiatric services with medication, weekly individual therapy and coun-
selling, and specialised groups of cognitive-behavioural work, anger management, therapy and edu-
cation, domestic violence, parenting, and weekly drug/alcohol therapy, with a 72-hour course on sub-
stance abuse education and relapse prevention over 12 months (n = 94)
Setting: prison
Length of treatment: a variety of activities including a 72-hour course up to 12 months
Length of follow-up: 12 months post prison release
Outcomes Criminal activity regarding a new offence (official records)
Incarceration for a new offence (official records)
Drug use (self-report)
Notes Funding: contract/grant sponsor: National Institute on Drug Abuse (NIDA); contract/grant number: P50
DA7700.0003
Conflict of interest: no declaration of interest reported by study authors
Sacks 2004 
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Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Methods used for random sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Method used for concealment not reported
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk No information on blinding reported
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk No information on blinding reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Some differences between groups: at follow-up, 82% for the (I) group and 69%
for the (C) group. ITT was performed and missing data were added to the data
set
Selective reporting (re-
porting bias)
Unclear risk Protocol for trial not identified. Measures reported in the methods of the pa-
per provide some information and concur with the outcomes reported in the
results section of the paper
Sacks 2004  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 573 adult women
Mean age 35.6 (SD 7.5)
100% female
47.8% white
99% drug-using
Eligibility criteria: female inmates with at least 6 months remaining until parole with serious sub-
stance abuse problems requiring treatment and presenting a minimum/medium security risk
Interventions Therapeutic community programme vs cognitive-behavioural intervention
Experimental intervention: the therapeutic community group received a modified intervention for
male inmates with co-occurring serious mental and substance use disorders. The intervention involved
a 6-month tenure in a separate residential building, with programme activities supplemented by peer-
led activities on weekends, and a further 4 hours per day. The programme followed therapeutic com-
munity principles, with additional gender-specific aspects (n = 257)
Setting: prison
Length of treatment: 5 days per week for 4 hours per day (and supplemented on the weekend with ad-
ditional 4 hours per day); average time spent was 6.5 months
Length of follow-up: 6, 12, and 18 months post prison release
Sacks 2008 
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Control: the Intensive Outpatient Program is the standard treatment that the Colorado Department of
Corrections offers to all female offenders who have been classified as substance abusers. This interven-
tion is designed to address substance abuse and criminality, with focus on prevention of relapse and
recidivism. The Intensive Outpatient Program substance abuse treatment curriculum consists of a 90-
hour course, presented in an educational format (Strategies for Self-Improvement and Change, Wan-
burg & Milkman, 1998), utilising a cognitive-behavioural format to address underlying issues of sub-
stance use/abuse and criminal behaviour. Women in the programme can participate in multiple other
services facility-wide, including mental health assessments (n = 211)
Setting: prison
Length of treatment: 2 days per week for 2 hours per day. Duration was approximately between 6 and
9 months
Length of follow-up: 6, 12, and 18 months post prison release
Outcomes Criminal activity, arrest, and drug-related activity (self-reported)
Criminal record data (% incarcerated, mean days to incarceration)
Self-reported illegal drug use
Notes Funding: work supported by US Department of Health and Human Services, National Institutes of
Health, National Institute on Drug Abuse
Conflict of interest: no declarations of interest are noted by study authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information other than "were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk No information about whether assessors were blind
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk No information about whether assessors were blind
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No loss to follow-up for re-incarceration outcome, but loss to follow-up for
other outcomes unclear
Differences noted between data collected via self-report and official records.
Intention-to-treat analysis used to analyse outcome measures
Selective reporting (re-
porting bias)
Low risk No evidence of selective reporting
Sacks 2008  (Continued)
 
 
Methods Study design: RCT
Sacks 2011 
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Study grouping: parallel-group
Participants 127 adults
Mean age 38.2 years (SD 9.9)
100% male
56% white
100% co-occurring substance use and mental health problems
Alcohol use: unknown
61.8% with clinical level of psychological distress as measured by Global Severity Index
Eligibility criteria: male; diagnosed with co-occurring mental and substance use disorders; had partic-
ipated in 1 of 2 prison substance abuse treatment programmes; approved for placement in a communi-
ty corrections facility and accepted by the provider agency for placement in a community corrections
facility
Interventions Re-entry modified therapeutic community vs parole supervision case management
Experimental intervention: consisted of a residential programme of 6 months' duration. Participants
had progressively increasing independence, eventually being responsible for providing counsel, guid-
ance, and coaching for new members. Participants also worked in the community and saved money
for independent living. There were weekly group psychoeducational classes to address the interrela-
tionship between mental disorders and substance abuse, as well as various other group and individ-
ual counselling sessions. Medication monitoring and psychiatric services were provided on-site. Partici-
pants were given assistance with housing and encouragement for employment (n = 71)
Setting: prison
Length of treatment: 3 to 7 days per week, 3 to 5 hours each day for 6 months
Length of follow-up: 12 months post prison release
Control: participants were released to a community corrections facility and leC the facility during the
day to go to work, have treatment, and report to parole officers. Control consisted of outreach and en-
gagement activities, brokering community-based services, and direct provision of support and coun-
selling services. There was a weekly relapse prevention group and daily medication monitoring. Psy-
chiatric and substance abuse services were provided by outside agencies (community parole officers
helped clients choose). Unlike in the intervention, criminal thinking and behaviour were not specifical-
ly addressed. The average participant attended 1 group per week and had monthly psychiatric assess-
ments (n = 56)
Setting: transition from prison into the community
Length of treatment: 1 session per week for up to 6 months
Length of follow-up: 12 months post prison release.
Outcomes Rate of re-incarceration
Number of days until re-incarceration
Involvement in self-reported criminal activity
Number of days until self-reported criminal activity
Alcohol and drug offences (self-reported)
Other offences (self-reported)
Sacks 2011  (Continued)
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Notes Funding: this project received support from the Department of Health and Human Services, National
Institutes of Health, NIDA (Grant 5R01DA019982-[01-05])
Conflict of interest: no declarations of interest reported by study authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number list
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk No information about blinding presented
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk No information about blinding presented
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Intent-to-treat analyses conducted
Selective reporting (re-
porting bias)
Unclear risk Outcomes reported in the methods section of the paper and in the outcomes
list. No protocol obtained
Sacks 2011  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 189 adolescents
Mean age 17.12 years (SD 1.10). Range 14 to 19 years
85.7% male
32.8% white
88.9% marijuana use
63% alcohol use
68.5% had significant depressive symptoms during past week at baseline (CES-D)
Eligibility criteria: 14 to 19 years old, sentenced to juvenile correctional facility for 4 to 12 months, en-
gaged in at least monthly marijuana use or binge-drinking in the year before incarceration, used any al-
cohol or marijuana in the month before incarceration (or before committing the offence leading to in-
carceration)
Interventions Secure establishment-based motivational interviewing vs relaxation treatment
Stein 2011 
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Experimental intervention: the intervention was designed specifically to reduce substance use and its
associated risks and consequences. Treatment was manualised. Motivational interviewing focused on
empathy, not arguing, developing discrepancy, self-efficacy, and personal choice (n = 96)
Setting: prison
Length of treatment: 90-minute baseline intervention and 60-minute booster session within 2 weeks
of release
Length of follow-up: 3 months post release
Control: involved relaxation techniques as well as advice on risky behaviours associated with sub-
stance use. Intervention included progressive muscle relaxation, use of guided imagery, and feedback
on use of techniques (n = 85)
Setting: prison
Length of treatment: 90-minute baseline intervention and 60-minute booster session within 2 weeks
of release
Length of follow-up: 3 months post release
Outcomes Mean number of joints per day
Mean percentage of days used marijuana
Notes Funding: this research was supported by National Institute on Drug Abuse Grant R01 #13375 (to L.A.R.
Stein, principal investigator)
Conflict of interest: no declaration of interest reported by study authors
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Random assignment using a random number table"
Allocation concealment
(selection bias)
Unclear risk "Random number was placed in an envelope and opened by research sta- af-
ter the baseline assessment"
No information given about whether envelopes were sequentially numbered,
opaque, or sealed
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk Follow-up assessments at 3 months were completed blind by researchers but
not at any other time point
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk Follow-up assessments at 3 months were completed blind by researchers but
not at any other time point
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 8/71 were lost to follow-up in the RMTC group, and 9/56 were lost to follow-up
in the PSCM group. ITT was conducted for the secondary outcome of criminal
activity
Selective reporting (re-
porting bias)
Unclear risk Measures reported in the paper but protocol could not be located
Stein 2011  (Continued)
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Methods Study design: RCT
Study grouping: parallel-group
Participants 156 adolescents
Mean age 15.00 years (SD 1.35)
61% male
30/156 Asian
% drug use not reported
% alcohol use not reported
Eligibility criteria: target group was defined as youths 12 to 17 years of age who fulfilled the criteria
for a clinical diagnosis of conduct disorder according to the Diagnostic and Statistical Manual of Mental
Disorders (Fourth Edition, Text Revision) (DSM–IV–TR; American Psychiatric Association, 2000) and whose
parent(s) or parent surrogate(s) were motivated to engage in an intervention
Interventions Multi-systemic treatment (MST) Intervention vs treatment as usual
Experimental intervention: MST is an intensive family- and community-based treatment for adoles-
cents with serious clinical problems that include criminal behaviour, violence, substance abuse, and
serious emotional disturbance (e.g. Henggeler, Sheidow, & Lee; in press). In the home and community,
MST provides service delivery based on the family’s needs. Therapists are available to families 24 hours
a day, 7 days a week. By working with parents, teachers, and others, MST aims to restructure a youth’s
ecology to support prosocial development and decrease delinquent behaviour (n = 79)
Setting: community
Length of treatment: average between 4 and 6 months' duration
Length of follow-up: 7 months after referral
Control: youths assigned to the group receiving TAU were referred back to social services for deter-
mination of intervention. The most common intervention received by this group was individual coun-
selling (1 to 2 hours every other week) provided by the case manager or a private counsellor and fi-
nanced by the Social Welfare Administration (n = 20). The second most common was family therapy (n
= 16). Other TAU services included mentorship with non-professional volunteers spending time with
youths (normally 10 hours a month on 2 or more occasions; n = 12), out-of home care, and primarily
residential care (n = 8). Less frequent services were aggression replacement training (n = 4), addiction
treatment (n = 2), and special education services (n = 2). Thirteen youths in this group received no ser-
vices. Of those 64 receiving services, 16 (25%) were prematurely interrupted (i.e. original services were
replaced for a new intervention during 7-month follow-up) (n = 77)
Setting: community
Length of treatment: not reported
Length of follow-up: 7 months after referral
Outcomes Self-report delinquency
Alcohol and drug consumption
Alcohol Use Disorder Identification Test (AUDIT)
Drug Use Disorder Indentification Test (DUDIT)
Sundell 2008 
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Notes Funding: support for this research was provided by the Institute for Evidence-Based Social Work Prac-
tice, National Board of Health and Welfare, Sweden, Mobilisering mot narkotika, Ministry of Health and
Social Affairs, Sweden, and the cities of Go teborg, Halmstad, Malmo, and Stockholm, Sweden
Conflict of interest: none of the study authors had any financial interest in MST
Country: Sweden
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation
Allocation concealment
(selection bias)
Low risk Quote: "After research sta- received completed instruments from both the
youths and parents, research sta- opened a sealed and numbered envelope
that contained the results of the computer- generated randomization for that
specific youth. In a central location separate from the data collection loca-
tions, the contents of the sealed envelopes were determined before the refer-
ral process began. The principal investigator was the only member of the re-
search team to have access to the randomization sequence"
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The number of missing subjects at post measure varied between 14 (9%) and
19 (12%) for youths, and between 12 (8%) and 18 (12%) for guardians, with the
exception of Guardian’s Mental Health, for which the number of missing sub-
jects was 30 (19%)
Selective reporting (re-
porting bias)
Unclear risk No protocol available. Measures reported in the methods section of the paper
matched outcomes in the results
Sundell 2008  (Continued)
 
 
Methods Study design: RCT
Study grouping: parallel-group
Participants 715 adults
Mean age 30.9 years (SD 7.4)
100% male
37.8% white
100% drug-using
Alcohol use not reported
100% psychiatric history
Eligibility criteria: offenders with a drug problem who were 9 to 14 months from parole; offenders
convicted of arson or sexual crimes against minors were not eligible
Interventions Therapeutic community (TC) and voluntary residential aftercare vs no-treatment waiting list control
Wexler 1999 
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Experimental intervention: TC included a 2- to 3-month orientation phase including clinical assess-
ment of residential needs and problem areas and planning of interventions and goals. During the sec-
ond phase, 5- to 6-month treatment stage, residents were provided opportunities to earn positions
of increasing responsibility. Groups and counselling sessions focused on self-discipline, self-worth,
self-awareness, respect for authority, and acceptance of guidance for problem areas. During the re-
entry phase (taking up to 3 months), residents used their planning and decision-making skills and
worked with programme and parole sta- to prepare for their return to the community. Graduates of
the scheme were given the opportunity to participate in a community-based TC for up to 12 months (n
= 247)
Setting: prison and release into the community TC
Length of treatment: total duration (including aftercare option) up to 24 months
Length of follow-up: 12, 24, and 36 months
Control: no-treatment waiting list control group (n = 290)
Setting: prison
Length of treatment: total duration up to 14 months
Length of follow-up: 12, 24, and 36 months
Outcomes Incarceration (official records)
Arrest for any offence (self-report)
Arrest for a drug offence (self-report)
Drug use (self-report)
Notes Funding: this study was a co-operative effort by the Center for Therapeutic Community Research at
National Development and Research Institutes, Inc., and the California Department of Corrections and
Rehabilitation Office of Substance Abuse Programs. The evaluation was funded by the National Insti-
tute of Drug Abuse, Grant #PAODA07700-01
Conflict of interest: not reported
Country: USA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants were "randomly" assigned and stratified by ethnic makeup
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of outcome as-
sessment (detection bias) 
subjective outcomes
Unclear risk No information on blinding provided
Blinding of outcome as-
sessment (detection bias) 
objective outcomes
Unclear risk No information on blinding provided
Incomplete outcome data
(attrition bias) 
Low risk ITT analyses conducted
Wexler 1999  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Unclear risk Protocol not obtained. Measures reported in the methods section of the paper
comparable with outcomes in the results section
Wexler 1999  (Continued)
ACT: acceptance and commitment therapy; AGT: adolescent group therapy; AUDIT: Alcohol Use Disorder Identification Test; CBT: cogni-
tive-behavioural therapy; CES-D: Center for Epidemiologic Studies Depression Scale; CSAT: Center for Substance Abuse Treatment; DBT:
dialectical behavioural therapy; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DUDIT: Drug Use Disorder
Identification Test; ITT: intention-to-treat; JDC: juvenile drug court; MBI: mindfulness-based intervention; MBRP: mindfulness-based re-
lapse prevention; MDD: major depressive disorder; MDFT: multi-dimensional family therapy; MHTC: mental health treatment court; MI:
motivational interviewing; MST: multi-systemic treatment; PANSS: Positive and Negative Symptoms Scale; R&R: Reasoning & Rehabilita-
tion; RCT: randomised controlled trial; SCID: Structured Clinical Interview for DSM Disorders; SD: standard deviation; TAU: treatment as
usual; TC: therapeutic community.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alemagno 2009 Not measuring drug or crime outcomes
Alemi 2010 Not a mental health population
Allen 2017 Not measuring drug or crime outcomes
Althoff 2013 Not a randomised controlled trial
Anonymous 1989 Not a randomised controlled trial
Anonymous 2004 Not an offender population
Anonymous 2014 Conference proceeding only, without useful data
Anonymous 2015 Conference proceeding only, without useful data
Anonymous 2015a Not a randomised controlled trial
Anonymous 2016 Conference proceeding only, without useful data
Anonymous 2016a Not measuring drug or crime outcomes
Anonymous 2016b Not a randomised controlled trial
Bailey 1994 Not a randomised controlled trial
Barrett 2015 Not measuring drug or crime outcomes
Bartlett 2015 Not measuring drug or crime outcomes
Bawor 2014 Not an offender population
Bazazi 2017 Not a randomised controlled trial
Berman 2004 Not a mental health population
Bermudez 2014 Not a randomised controlled trial
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Study Reason for exclusion
Brahen 1976 Not a randomised controlled trial
Brodie 2009 Not a mental health population
Brovko 2017 Not measuring drug or crime outcomes
Brown 2013 Not a mental health population
Brown 2014 Not a randomised controlled trial
Burraston 2014 Not a randomised controlled trial
Bustos 2016 Not measuring drug or crime outcomes
Calcaterra 2014 Not a randomised controlled trial
Calsyn 2005 Not an offender population
Carrieri 2017 Not an offender population
Carroll 2006 Not a mental health population
Carroll 2012 Not a mental health population
Chandler 2016 Not a mental health population
Chaple 2014 Not a mental health population
Chaple 2016 Not a mental health population
Cheesman 2016 Not a randomised controlled trial
Cihlar 2014 Not a randomised controlled trial
Clair 2013 Not a randomised controlled trial
Clair-Michaud 2016 Not measuring drug or crime outcomes
Clark 2002 Not a randomised controlled trial
Clayton 2013 Not measuring drug or crime outcomes
Compton 2016 Not a randomised controlled trial
Coulton 2017 Not a mental health population
Curtis 2015 Not a randomised controlled trial
Czuchry 2000 Not measuring drug or crime outcomes
Czuchry 2003 Not measuring drug or crime outcomes
D'Amico 2013 Not a mental health population
Dakof 2010 Not a mental health population
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Study Reason for exclusion
Davis 2015 Not a randomised controlled trial
Day 2006 Not an offender population
Demaret 2015 Not an offender population
Di Paola 2014 Not a mental health population
Dickson 2017 Not a randomised controlled trial
Dolan 2003 Not a mental health population
Dolan 2005 Not a mental health population
Dole 1969 Not a mental health population
Doyle 2015 Not a randomised controlled trial
Doyle 2016 Not a randomised controlled trial
Dunlop 2017 Not an offender population
Easton 2007 Not a randomised controlled trial
Easton 2017 Not a mental health population
Egg 2000 Not a mental health population
Franck 2012 Not a mental health population
Friedmann 2015 Conference proceeding only, without useful data
Friedmann 2017 Not a mental health population
Ginsberg 2012 Not measuring drug or crime outcomes
Ginsberg 2015 Not measuring drug or crime outcomes
Ginsberg 2015a Not measuring drug or crime outcomes
Gisev 2015 Not a randomised controlled trial
Gisev 2015a Not a randomised controlled trial
Gisev 2015b Not a randomised controlled trial
Goddard-Eckrich 2018 Not measuring drug or crime outcomes
Goorden 2015 Not an offender population
Gordon 2014 Not measuring drug or crime outcomes
Gordon 2015 Not a randomised controlled trial
Gordon 2017 Not a mental health population
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Study Reason for exclusion
Gordon 2017a Not a mental health population
Gottfredson 2005 Not a mental health population
Haig 2003 Not a randomised controlled trial
Hanlon 1975 Not a mental health population
Hanlon 1977 Not a mental health population
Harada 2012 Not measuring drug or crime outcomes
Heimer 2006 Not a randomised controlled trial
Henderson 2010 Not a mental health population
Henderson 2016 Not a mental health population
Hendriks 2011 Not an offender population
Henggeler 2006 Not a mental health population
Herrman 2016 Not an offender population
Himelstein 2014 Not measuring drug or crime outcomes
Himelstein 2015 Not a randomised controlled trial
Hoffman 1996 Not an offender population
Holloway 2006 Not a mental health population
Hser 2013 Not an offender population
Jalali 2017 Not measuring drug or crime outcomes
Jason 2007 Not an offender population
Jason 2015 Not a mental health population
Jason 2016 Not a randomised controlled trial
Jerrell 1995 Not an offender population
Joe 1997 Not an offender population
Kearley 2018 Not a mental health population
Kelly 2016 Not measuring drug or crime outcomes
Kinlock 2007 Not a mental health population
Kinlock 2009 Not a mental health population
Knight 2016 Not measuring drug or crime outcomes
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Study Reason for exclusion
Knudsen 2014 Not measuring drug or crime outcomes
Knudsen 2016 Not a randomised controlled trial
Kongsakon 2005 Not measuring drug or crime outcomes
Konstenius 2014 Not a mental health population
Kopak 2015 Not a randomised controlled trial
Krebs 2017 Not a randomised controlled trial
Kua 2014 Not an offender population
Kubiak 2016 Not a randomised controlled trial
Kurland 1975 Not a mental health population
Kurniasanti 2014 Not a randomised controlled trial
Lee 2011 Not measuring drug or crime outcomes
Lee 2013 Not a randomised controlled trial
Lee 2014 Not measuring drug or crime outcomes
Lee 2014b Not measuring drug or crime outcomes
Lee 2014c Conference proceedings only, without useful data
Lee 2015 Conference proceedings only, without useful data
Lee 2015a Not a mental health population
Lee 2015b Not a mental health population
Lee 2016 Not a mental health population
Lee 2016a Not a mental health population
Lehman 2015 Not measuring drug or crime outcomes
Lerch 2017 Not a mental health population
Liddle 2011 Not measuring drug or crime outcomes
Lintzeris 2006 Not an offender population
Little 1993 Not an offender population
Lo 2012 Not a mental health population
Lobmann 2007 Not a mental health population
Luciano 2014 Not an offender population
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Study Reason for exclusion
Magura 2009 Not a mental health population
March 2006 Not a mental health population
Marinelli-Casey 2008 Not a randomised controlled trial
Marlowe 2008 Not a mental health population
Marlowe 2009 Not a mental health population
Marsch 1998 Systematic review
Martin 2010 Not measuring drug or crime outcomes
Martin 2011 Not an offender population
Martin 2014 Not an offender population
Martin 2015 Not measuring drug or crime outcomes
Martin 2017 Not an offender population
Mazerolle 2000 Not an offender population
McAuliffe 1990 Not an offender population
McCollister 2014 Not a randomised controlled trial
McCollister 2015 Conference proceeding only, without useful data
McCollister 2016 Not an offender population
McCollister 2017 Not a randomised controlled trial
McDonald 2016 Not a mental health population
McKenzie 2012 Not a mental health population
Meade 2017 Not a mental health population
Metrebian 2015 Not an offender population
Mitchell 2013 Not an offender population
Mitchell 2014 Not an offender population
Murphy 2017 Not a mental health population
Nemes 1999 Not a mental health population
Nirenberg 2013 Not measuring drug or crime outcomes
Nirenberg 2013a Not measuring drug or crime outcomes
Nosyk 2010 Not an offender population
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Study Reason for exclusion
Nyamathi 2014 Not a randomised controlled trial
Nyamathi 2014a Not a randomised controlled trial
Nyamathi 2015 Not measuring drug or crime outcomes
Nyamathi 2016 Not a randomised controlled trial
Nyamathi 2017a Not a mental health population
O'Brien 2015 Not a randomised controlled trial
O'Brien 2017 Not a randomised controlled trial
Owens 2016 Not measuring drug or crime outcomes
Owens 2017 Not measuring drug or crime outcomes
Page 1982 Not measuring drug or crime outcomes
Parmar 2017 Not a mental health population
Pettus-Davis 2017 Not measuring drug or crime outcomes
Pierce 2018 Not a randomised controlled trial
Pijl 2017 Not a randomised controlled trial
Pitre 1997 Not measuring drug or crime outcomes
Pitre 1998 Not measuring drug or crime outcomes
Poblete 2017 Not an offender population
Prendergast 2015 Not measuring drug or crime outcomes
Prendergast 2017 Not a mental health population
Rich 2015 Not a mental health population
Roll 2005 Not an offender population
Rounsaville 2008 Not a mental health population
Rowe 2007 Not an offender population
Rowland 2008 Not a randomised controlled trial
Sajatovic 2013 Not an offender population
Saxena 2014 Not measuring drug or crime outcomes
Schaeffer 2014 Not a mental health population
Schwartz 2014 Not a mental health population
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Study Reason for exclusion
Schwartz 2016 Not a mental health population
Schwartz 2016a Not a mental health population
Schwartz 2016b Not a mental health population
Scott 2017 Not measuring drug or crime outcomes
Seitz-Brown 2015 Conference proceedings only, without useful data
Shaul 2016 Not a mental health population
Sheard 2007 Not a randomised controlled trial
Sheard 2009 Not a mental health population
Sheard 2009a Not a mental health population
Shearer 2003 Not an offender population
Shearer 2007 Not a randomised controlled trial
Sinha 2003 Not a mental health population
Smith 2017 Not an offender population
Somers 2013 Not measuring drug or crime outcomes
Spohr 2015 Not measuring drug or crime outcomes
Springer 2017 Not measuring drug or crime outcomes
Stein 2011a Not a mental health population
Sticca 2014 Not a randomised controlled trial
Stillwell 2017 Not a randomised controlled trial
Strang 2000 Not an offender population
Strang 2013 Halted part of the way through
Swogger 2016 Not a mental health population
Tolou-Shams 2011 Not measuring drug or crime outcomes
Vagenas 2017 Not measuring drug or crime outcomes
van Stelle 2004 Not a randomised controlled trial
Vaucher 2016 Not measuring drug or crime outcomes
Villagra 2013 Not a mental health population
Warren 2006 Not an offender population
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Study Reason for exclusion
Welsh 2014 Not measuring drug or crime outcomes
Wimberly 2018 Not measuring drug or crime outcomes
Witkiewitz 2014 Not measuring drug or crime outcomes
Wol- 2012 Not a randomised controlled trial
Wooditch 2015 Not a randomised controlled trial
Wooditch 2017 Not measuring drug or crime outcomes
Wright 2011 Not a mental health population
Zlotnick 2003 Not measuring drug or crime outcomes
Zlotnick 2009a Not a mental health population
RCT: randomised controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title "CAN Stop" - Implementation and evaluation of a secondary group prevention for adolescent and
young adult cannabis users in various contexts - study protocol
Methods The CAN Stop study is a 4-armed randomised wait list controlled trial. The 4 arms are needed for
the different help system settings, in which the CAN Stop training programme is evaluated: (a) the
drug addiction aid and youth welfare system, (b) the outpatient medical system, (c) the in-patient
medical system, and (d) prisons for juvenile offenders. Data are collected at 3 points: before and af-
ter training or treatment as usual and 6 months after completion of either intervention
Participants Young adult cannabis users
Interventions (a) the drug addiction aid and youth welfare system, (b) the outpatient medical system, (c) the in-
patient medical system, and (d) prisons for juvenile offenders
Outcomes Sociodemographics; Living situation; Social network; Problems with school, police, debts; Educa-
tion; Prior counselling and therapies; Screening for acute psychosis; Subscale of the Diagnostisches
Interview psychischer Störungen (DIPS; diagnostic Interview for psychiatric disorders); Substance
use history; Society for Addiction Research and Therapy); Severity of dependence; Severity of de-
pendence scale (Psychosocial adjustment; Youth self-report; Young adult self-report) (participants
aged 18 to 21); Expected positive and negative effects of cannabis use; Comprehensive Cannabis
Expectancy Questionnaire (CCEQ); Relationship to friends and peers; Questionnaire for health-re-
lated quality of life (Kiddo-KINDL Revised); Family relationships; Motivation for change in cannabis
use; Questionnaire to protocol the willingness for change; Personal goals with regard to changes in
substance use; Self-efficacy with regard to cannabis abstinence or limited cannabis use; Satisfac-
tion with training; Peer resistance regarding cannabis use
Starting date Not reported
Contact information cbaldus@uke.uni-hamburg.de
Notes Trial registration: ISRCTN: ISRCTN57036983
Baldus 2011 
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Trial name or title Evaluation of the Housing First program in patients with severe mental disorders in France: study
protocol for a randomised controlled trial
Methods Prospective randomised trial designed to assess the impact of a Housing First intervention on
health outcomes and costs over a period of 24 months on homeless people with severe mental ill-
ness, compared to treatment as usual. The study is being conducted in 4 cities in France: Lille, Mar-
seille, Paris, and Toulouse
Participants Inclusion criteria are as follows: over 18 years of age, absolutely homeless or in precarious housing,
possessing a 'high' level of need: diagnosis of schizophrenia or bipolar disorder and moderate to
severe disability according to the Multnomah Community Ability Scale (score ≤ 62) and at least 1 of
the following 3 criteria: (1) having been hospitalised for mental illness 2 or more times in any single
year over the preceding 5 years; (2) comorbid alcohol or substance use; and (3) having been recent-
ly arrested or incarcerated. A total of 300 individuals per group will be included
Interventions Housing First Intervention or Treatment As Usual; the Housing First intervention provides immedi-
ate access to independent housing and community care
Outcomes Primary outcome criterion is use of high-cost health services (i.e. number of hospital admissions
and number of emergency department visits) during the 24-month follow-up period. Secondary
outcome measures include health outcomes, social functioning, housing stability, and contact with
police services. An evaluation of the cost-effectiveness and cost utility of Housing First will also be
conducted
Starting date The study started to recruit participants in August 2011; recruitment is ongoing
Contact information pascal.auquier@univ-amu.fr
Notes  
Tinland 2013 
 
 
Trial name or title Jail-to-community treatment continuum for adults with co-occurring substance use and mental
disorders: study protocol for a pilot randomised controlled trial
Methods Adaptations to DDMI and IGT were guided by the Risk-Need-Responsivity model and the Nation-
al Institute of Corrections' implementation competencies; development of the implementation
framework and communication protocols were guided by the Evidence-Based Interagency Imple-
mentation Model for community corrections and the Inter-organizational Relationship model, re-
spectively. Implementation and evaluation of protocols and adapted interventions will occur via
an open trial and a pilot randomised trial. The clinical intervention consists of 2 in-jail DDMI ses-
sions and 12 in-community IGT sessions. Twelve adults with CODs and 4 clinicians will participate
in the open trial to evaluate the acceptability and feasibility of, and fidelity to, the interventions
and research and communication protocols. The pilot controlled trial will be conducted with 60 in-
mates who will be randomised to either DDMI-IGT or treatment as usual. Baseline assessment will
be conducted in jail, and 4 community-based assessments will be conducted during a 6-month fol-
low-up period. Implementation, clinical, public health, and treatment preference outcomes will be
evaluated
Participants Inmate participants will be broadly representative of adults with co-occurring mental and sub-
stance use disorders in a large urban county jail
Interventions Dual-diagnosis motivational interviewing (DDMI) and integrated group therapy (IGT) vs treatment
as usual
VanDorn 2017 
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Outcomes 6 and 12 months HIV treatment (HIV-1 RNA levels, CD4 count, ART adherence, retention in care),
substance abuse (time to relapse to opioid use, % opioid negative urine samples, opioid craving),
adverse side effects and HIV risk behaviour (sexual and drug-related risks)
The public health relevance is that outcomes from this study will establish the efficacy, safety, and
tolerability of pharmacological therapy using naltrexone treatment among HIV+s and will establish
depot-naltrexone treatment as an effective, evidence-based treatment for opioid dependence for
released HIV+ prisoners
Starting date 2012
Contact information Yale University
Notes  
VanDorn 2017  (Continued)
ART: Antiretroviral therapy; COD: co-occurring disorders; NTX: naltrexone.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Therapeutic community and aAercare vs treatment as usual
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Criminal activity 2 532 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.42, 0.77]
1.1 Any criminal activity 2 266 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.53, 0.84]
1.2 Re-incarceration 2 266 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.24, 0.67]
 
 
Analysis 1.1.   Comparison 1 Therapeutic community and
aAercare vs treatment as usual, Outcome 1 Criminal activity.
Study or subgroup Therapeutic
community
Treatment
as usual
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Any criminal activity  
Sacks 2004 35/75 43/64 37.74% 0.69[0.52,0.93]
Sacks 2011 28/71 35/56 32.76% 0.63[0.44,0.9]
Subtotal (95% CI) 146 120 70.49% 0.67[0.53,0.84]
Total events: 63 (Therapeutic community), 78 (Treatment as usual)  
Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%  
Test for overall effect: Z=3.49(P=0)  
   
1.1.2 Re-incarceration  
Sacks 2004 7/75 21/64 11.7% 0.28[0.13,0.63]
Sacks 2011 13/71 21/56 17.81% 0.49[0.27,0.89]
Subtotal (95% CI) 146 120 29.51% 0.4[0.24,0.67]
Total events: 20 (Therapeutic community), 42 (Treatment as usual)  
Favours TC 1000.01 100.1 1 Favours TAU
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Study or subgroup Therapeutic
community
Treatment
as usual
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.02; Chi2=1.17, df=1(P=0.28); I2=14.3%  
Test for overall effect: Z=3.49(P=0)  
   
Total (95% CI) 292 240 100% 0.57[0.42,0.77]
Total events: 83 (Therapeutic community), 120 (Treatment as usual)  
Heterogeneity: Tau2=0.04; Chi2=5.31, df=3(P=0.15); I2=43.54%  
Test for overall effect: Z=3.67(P=0)  
Test for subgroup differences: Chi2=3.24, df=1 (P=0.07), I2=69.12%  
Favours TC 1000.01 100.1 1 Favours TAU
 
 
Comparison 2.   Therapeutic community and aAercare vs cognitive-behavioural therapy
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Self-reported drug use at 6 months 1 314 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.46, 1.32]
2 Arrested any for 6 months 1 314 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.44, 1.09]
3 Criminal activity at 6 months 1 314 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.52, 1.05]
4 Drug-related crime 1 314 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.56, 1.36]
 
 
Analysis 2.1.   Comparison 2 Therapeutic community and aAercare vs cognitive-
behavioural therapy, Outcome 1 Self-reported drug use at 6 months.
Study or subgroup Therapeutic
community
and aftercare
Cognitive
behavioural
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sacks 2008 22/163 26/151 100% 0.78[0.46,1.32]
   
Total (95% CI) 163 151 100% 0.78[0.46,1.32]
Total events: 22 (Therapeutic community and aftercare), 26 (Cognitive be-
havioural)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
Favours TC and aftercare 1000.01 100.1 1 Favours CBT
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Analysis 2.2.   Comparison 2 Therapeutic community and aAercare vs
cognitive-behavioural therapy, Outcome 2 Arrested any for 6 months.
Study or subgroup Therapeutic
community
and aftercare
Cognitive
behavioural
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sacks 2008 26/163 35/151 100% 0.69[0.44,1.09]
   
Total (95% CI) 163 151 100% 0.69[0.44,1.09]
Total events: 26 (Therapeutic community and aftercare), 35 (Cognitive be-
havioural)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.6(P=0.11)  
Favours TC and aftercare 1000.01 100.1 1 Favours CBT
 
 
Analysis 2.3.   Comparison 2 Therapeutic community and aAercare vs
cognitive-behavioural therapy, Outcome 3 Criminal activity at 6 months.
Study or subgroup Therapeutic
community
and aftercare
Cognitive
behavioural
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sacks 2008 40/163 50/151 100% 0.74[0.52,1.05]
   
Total (95% CI) 163 151 100% 0.74[0.52,1.05]
Total events: 40 (Therapeutic community and aftercare), 50 (Cognitive be-
havioural)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.67(P=0.1)  
Favours TC and aftercare 1000.01 100.1 1 Favours CBT
 
 
Analysis 2.4.   Comparison 2 Therapeutic community and aAercare
vs cognitive-behavioural therapy, Outcome 4 Drug-related crime.
Study or subgroup Therapeutic
community
and aftercare
Cognitive
behavioural
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sacks 2008 30/163 32/151 100% 0.87[0.56,1.36]
   
Total (95% CI) 163 151 100% 0.87[0.56,1.36]
Total events: 30 (Therapeutic community and aftercare), 32 (Cognitive be-
havioural)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.62(P=0.54)  
Favours TC and aftercare 1000.01 100.1 1 Favours CBT
 
 
Interventions for drug-using oenders with co-occurring mental health problems (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
77
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Comparison 3.   Therapeutic community vs waiting list control
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Re-incarceration at 36 months 1 478 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.46, 0.79]
 
 
Analysis 3.1.   Comparison 3 Therapeutic community vs
waiting list control, Outcome 1 Re-incarceration at 36 months.
Study or subgroup Therapeutic
community
waiting
list control
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wexler 1999 69/289 75/189 100% 0.6[0.46,0.79]
   
Total (95% CI) 289 189 100% 0.6[0.46,0.79]
Total events: 69 (Therapeutic community), 75 (waiting list control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.68(P=0)  
Favours TC 1000.01 100.1 1 Favours WLC
 
 
Comparison 4.   Mental health treatment court with assertive case management vs treatment as usual
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Committing a new crime 1 235 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.62, 1.01]
2 Re-incarceration to jail at 12 months 1 235 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.91, 1.24]
3 ASI drug use at 12 months 1 235 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.03, 0.03]
 
 
Analysis 4.1.   Comparison 4 Mental health treatment court with assertive
case management vs treatment as usual, Outcome 1 Committing a new crime.
Study or subgroup Mental health
treatment
Treatment
as usual
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Cosden 2003 64/137 58/98 100% 0.79[0.62,1.01]
   
Total (95% CI) 137 98 100% 0.79[0.62,1.01]
Total events: 64 (Mental health treatment), 58 (Treatment as usual)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.91(P=0.06)  
Favours MHTC 1000.01 100.1 1 Favours TAU
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Analysis 4.2.   Comparison 4 Mental health treatment court with assertive case
management vs treatment as usual, Outcome 2 Re-incarceration to jail at 12 months.
Study or subgroup Mental health
treatment
Treatment
as usual
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Cosden 2003 104/137 70/98 100% 1.06[0.91,1.24]
   
Total (95% CI) 137 98 100% 1.06[0.91,1.24]
Total events: 104 (Mental health treatment), 70 (Treatment as usual)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.45)  
Favours MHTC 1000.01 100.1 1 Favours TAU
 
 
Analysis 4.3.   Comparison 4 Mental health treatment court with assertive case
management vs treatment as usual, Outcome 3 ASI drug use at 12 months.
Study or subgroup Mental health
treatment
Treatment as usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Cosden 2003 137 0.1 (0.1) 98 0.1 (0.1) 100% 0[-0.03,0.03]
   
Total *** 137   98   100% 0[-0.03,0.03]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours MHTC 10050-100 -50 0 Favours TAU
 
 
Comparison 5.   Motivational interviewing and cognitive skills vs waiting list control
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Abstinence from drug use at 6
months
1 31 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.73, 11.43]
2 ASI drug score at 6 months 1 31 Mean Difference (IV, Random, 95% CI) -0.04 [-0.37, 0.29]
 
 
Analysis 5.1.   Comparison 5 Motivational interviewing and cognitive skills
vs waiting list control, Outcome 1 Abstinence from drug use at 6 months.
Study or subgroup Motivational
interviewing
Waiting
list control
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Lanza 2014 8/18 2/13 100% 2.89[0.73,11.43]
   
Total (95% CI) 18 13 100% 2.89[0.73,11.43]
Total events: 8 (Motivational interviewing), 2 (Waiting list control)  
Favours motivational 1000.01 100.1 1 Favours WLC
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Study or subgroup Motivational
interviewing
Waiting
list control
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Favours motivational 1000.01 100.1 1 Favours WLC
 
 
Analysis 5.2.   Comparison 5 Motivational interviewing and cognitive
skills vs waiting list control, Outcome 2 ASI drug score at 6 months.
Study or subgroup Motivational
interviewing
Waiting list control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Lanza 2014 18 0.4 (0.6) 13 0.4 (0.4) 100% -0.04[-0.37,0.29]
   
Total *** 18   13   100% -0.04[-0.37,0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.24(P=0.81)  
Favours motivational 10050-100 -50 0 Favours WLC
 
 
Comparison 6.   Motivational interviewing and cognitive skills vs treatment as usual
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Marjuana frequency at 3
months
1 40 Mean Difference (IV, Random, 95% CI) -1.05 [-2.39, 0.29]
2 Arrest frequency 3 years post
release
1 31 Mean Difference (IV, Random, 95% CI) -0.66 [-1.31, -0.01]
3 Time to first arrest or offence 36
months post
1 31 Mean Difference (IV, Fixed, 95% CI) 0.87 [-0.12, 1.86]
4 Positive drug screen at 12
months
1 84 Mean Difference (IV, Fixed, 95% CI) -0.70 [-3.50, 2.10]
 
 
Analysis 6.1.   Comparison 6 Motivational interviewing and cognitive
skills vs treatment as usual, Outcome 1 Marjuana frequency at 3 months.
Study or subgroup Motivational
interviewing
Treatment as usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Malouf 2017 21 0.5 (1.2) 19 1.5 (2.7) 100% -1.05[-2.39,0.29]
   
Total *** 21   19   100% -1.05[-2.39,0.29]
Heterogeneity: Not applicable  
Favours motivational 10050-100 -50 0 FavoursTAU
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Study or subgroup Motivational
interviewing
Treatment as usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=1.54(P=0.12)  
Favours motivational 10050-100 -50 0 FavoursTAU
 
 
Analysis 6.2.   Comparison 6 Motivational interviewing and cognitive skills
vs treatment as usual, Outcome 2 Arrest frequency 3 years post release.
Study or subgroup Motivational
interviewing
Treatment as usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Malouf 2017 16 0.8 (0.8) 15 1.5 (1.1) 100% -0.66[-1.31,-0.01]
   
Total *** 16   15   100% -0.66[-1.31,-0.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.99(P=0.05)  
Favours motivational 10050-100 -50 0 FavoursTAU
 
 
Analysis 6.3.   Comparison 6 Motivational interviewing and cognitive skills vs
treatment as usual, Outcome 3 Time to first arrest or oence 36 months post.
Study or subgroup Motivational
interviewing
Treatment as usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Malouf 2017 16 2.5 (1.4) 15 1.6 (1.5) 100% 0.87[-0.12,1.86]
   
Total *** 16   15   100% 0.87[-0.12,1.86]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.72(P=0.09)  
Favours motivational 10050-100 -50 0 FavoursTAU
 
 
Analysis 6.4.   Comparison 6 Motivational interviewing and cognitive skills
vs treatment as usual, Outcome 4 Positive drug screen at 12 months.
Study or subgroup Motivational
interviewing
Treatment as usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Cullen 2012 44 2.6 (6.2) 40 3.3 (6.9) 100% -0.7[-3.5,2.1]
   
Total *** 44   40   100% -0.7[-3.5,2.1]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
Favours motivational 10050-100 -50 0 FavoursTAU
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Comparison 7.   Multi-systemic therapy vs treatment as usual
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Arrest by police 1 156 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.70, 1.36]
2 DUDIT scores 1 156 Mean Difference (IV, Random, 95% CI) -0.22 [-2.51, 2.07]
 
 
Analysis 7.1.   Comparison 7 Multi-systemic therapy vs treatment as usual, Outcome 1 Arrest by police.
Study or subgroup Multisys-
temic therapy
Treatment
as usual
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sundell 2008 37/79 37/77 100% 0.97[0.7,1.36]
   
Total (95% CI) 79 77 100% 0.97[0.7,1.36]
Total events: 37 (Multisystemic therapy), 37 (Treatment as usual)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours MST 1000.01 100.1 1 Favours TAU
 
 
Analysis 7.2.   Comparison 7 Multi-systemic therapy vs treatment as usual, Outcome 2 DUDIT scores.
Study or subgroup Multisys-
temic therapy
Treatment as usual Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Sundell 2008 79 3.3 (7.2) 77 3.6 (7.4) 100% -0.22[-2.51,2.07]
   
Total *** 79   77   100% -0.22[-2.51,2.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Favours MST 10050-100 -50 0 Favours TAU
 
 
Comparison 8.   Multi-systemic therapy vs adolescent substance treatment group
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Arrests between 6 and 24 months 1 112 Mean Difference (IV, Fixed, 95% CI) -0.24 [-0.76, 0.28]
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Analysis 8.1.   Comparison 8 Multi-systemic therapy vs adolescent
substance treatment group, Outcome 1 Arrests between 6 and 24 months.
Study or subgroup Multisys-
temic therapy
Substance Treat-
ment Group
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dakof 2015 55 1 (1.2) 57 1.2 (1.5) 100% -0.24[-0.76,0.28]
   
Total *** 55   57   100% -0.24[-0.76,0.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
Favours MST 10050-100 -50 0 Favours Substance Group
 
 
Comparison 9.   Interpersonal psychotherapy vs psychoeducational controls
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Substance abuse relapse at 3 months 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.30, 1.50]
 
 
Analysis 9.1.   Comparison 9 Interpersonal psychotherapy vs
psychoeducational controls, Outcome 1 Substance abuse relapse at 3 months.
Study or subgroup Interperson-
al psycho
Psychoe-
ducation
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Johnson 2012 6/19 9/19 100% 0.67[0.3,1.5]
   
Total (95% CI) 19 19 100% 0.67[0.3,1.5]
Total events: 6 (Interpersonal psycho), 9 (Psychoeducation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
Favours Ipsychotherapy 1000.01 100.1 1 Favours Psychoeducation
 
 
Comparison 10.   Legal defence services and wrap-around social work services vs legal defence work only
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Number of new offences committed at 12
months
1 29 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.07, 6.01]
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Analysis 10.1.   Comparison 10 Legal defence services and wrap-around social work services
vs legal defence work only, Outcome 1 Number of new oences committed at 12 months.
Study or subgroup Legal defence
and wrap
legal de-
fence only
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
McCarter 2016 2/22 1/7 100% 0.64[0.07,6.01]
   
Total (95% CI) 22 7 100% 0.64[0.07,6.01]
Total events: 2 (Legal defence and wrap), 1 (legal defence only)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.69)  
Favours defence and wrap 1000.01 100.1 1 Favours defence only
 
 
A D D I T I O N A L   T A B L E S
 
Study, year Criteria used for diagnoses Description of mental health problem
Cosden 2003 Determined by a psychiatrist/psychologist on the ba-
sis of a clinical interview and observations
Mood disorder
Schizophrenia
Bipolar disorder
Other
Dual diagnosis
Cullen 2012 Primary clinical diagnosis of a psychotic disorder. Di-
agnosis mechanism not reported
Schizophrenia
Schizoaffective disorder
Bipolar disorder
Other psychotic disorder
Dakof 2015 Diagnostic Interview Schedule for Children (DISC-2) -
identifying presence of mental disorders according to
the DSM-III 
Youth Self-Report
Presence of mental health disorders
Externalising subscales
Johnson 2012 Hamilton Rating Scale for Depression
Median duration of index episode in months
Number of depressive episodes
Number of previous suicide attempts
DSM-IV Axis I disorders using the SCID-I/II
Criteria for a major depressive disorder at least 4
weeks after substance abuse treatment
Minimum score of 18 on the Hamilton Rating Scale for
Depression
Lanza 2014 DSM-IV
Mini International Neuropsychiatric Interview
Anxiety Sensitivity Index
Anxiety
Mental health disorders
Antisocial personality disorder
Table 1.   Mental health diagnoses 
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Major depressive disorder
Generalised anxiety disorder
Malouf 2017 Borderline Personality Disorder Features assessed
with the Personality Assessment Inventory
Affective instability
Identity problems
Negative relationships
Impulsivity
McCarter 2016 Youth Self-Report that contain scales orientated to
the DSM-IV
Somatic complaints
Anxiety and depression
Social problems
Internalising and externalising (thought and attention
problems)
Sacks 2004 DIS Diagnosis of lifetime Axis I or Axis II mental disorder
Antisocial personality disorder
Sacks 2008 Global Severity Index
Beck Depression Inventory
Lifetime of mental health
PTSD Symptom Scale - Interview Posttraumatic Stress
Diagnostic Scale
Depression
PTSD
Lifetime of mental health
Sacks 2011 DSM-IV diagnostic criteria
Beck Depression Inventory
Post Traumatic Stress Disorder Symptom Scale
Brief Symptom Inventory
Global Severity Index
Depression
PTSD
Psychological distress
Stein 2011 CES-D Scale Scores > 16 indicate presence of significant depres-
sion; 69.8% had
significant depressive symptoms
Sundell 2008 DSM-IV diagnostic criteria
Youth Self-Report
Conduct disorder
Internalising and externalising
Total behaviour problems
Wexler 1999;
Prendergast 2003; 
Prendergast 2004
Not specified Antisocial personality disorder
Phobias
PTSD
Depression
Dysthymia
Table 1.   Mental health diagnoses  (Continued)
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Attention deficit hyperactivity disorder
Table 1.   Mental health diagnoses  (Continued)
CES-D: Center for Epidemiological Studies - Depression; DIS: Diagnostic Interview Schedule; DSM-IV: Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition; PTSD: post-traumatic stress disorder; SCID: Structured Clinical Interview for DSM Disorders.
 
 
A P P E N D I C E S
Appendix 1. MEDLINE (R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily,
and Ovid MEDLINE(R)
 
MEDLINE search
1 exp substance related disorders/ (274070)
2 street drugs/ (10355)
3 designer drugs/ (1439)
4 exp narcotics/ (120114)
5 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (100176)
6 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (491028)
7 1 or 2 or 3 or 4 or 5 or 6 (713470)
8 crime/ (15534)
9 criminals/ (4125)
10 prisoners/ (16035)
11 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (56176)
12 (offend$ or criminal$ or convict$ or felon$).ti,ab. (37983)
13 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (29693)
14 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (5525)
15 8 or 9 or 10 or 11 or 12 or 13 or 14 (126620)
16 7 and 15 (16717)
17 randomized controlled trial.pt. (516039)
18 controlled clinical trial.pt. (101743)
19 randomized.ab. (453171)
20 placebo.ab. (210619)
21 drug therapy.fs. (2199170)
22 randomly.ab. (312199)
23 trial.ab. (477783)
 
Interventions for drug-using oenders with co-occurring mental health problems (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
86
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
24 groups.ab. (1925728)
25 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 (4548008)
26 exp animals/ not humans.sh. (4814392)
27 25 not 26 (3934677)
28 16 and 27 (3760)
29 (201404$ or 201405$ or 201406$ or 201407$ or 201408$ or 201409$ or 201410$ or 201411$ or 201412$).ed. (771773)
30 (2015$ or 2016$ or 2017$).ed. (3473901)
31 ("20180101" or "20180102" or "20180103" or "20180104" or "20180105").ed. (19503)
32 29 or 30 or 31 (4265177)
33 28 and 32 (822)
  (Continued)
 
Appendix 2. Embase search strategy via Ovid
 
Embase search
1 substance abuse/ (49037)
2 drug dependence/ (46621)
3 addiction/ (49762)
4 drug abuse/ (49453)
5 intravenous drug abuse/ (9700)
6 opiate addiction/ (14284)
7 heroin dependence/ (8918)
8 cocaine dependence/ (11405)
9 morphine addiction/ (3077)
10 cannabis addiction/ (8306)
11 alcoholism/ (114191)
12 alcohol abuse/ (25949)
13 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (122248)
14 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (598185)
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 (773484)
16 exp crime/ (77511)
17 criminal behavior/ (7677)
18 criminal justice/ (5597)
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19 prisoner/ or offender/ (25391)
20 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (56577)
21 (offend$ or criminal$ or convict$ or felon$).ti,ab. (44660)
22 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (32476)
23 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (6561)
24 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (186404)
25 clinical trial/ (968061)
26 randomized controlled trial/ (482319)
27 randomization/ (76536)
28 single blind procedure/ (30101)
29 double blind procedure/ (145050)
30 crossover procedure/ (53840)
31 placebo/ (316535)
32 randomi?ed controlled trial$.tw. (170107)
33 rct.tw. (26496)
34 random allocation.tw. (1760)
35 randomly allocated.tw. (28885)
36 allocated randomly.tw. (2297)
37 (allocated adj2 random).tw. (874)
38 single blind$.tw. (20390)
39 double blind$.tw. (184823)
40 ((treble or triple) adj blind$).tw. (751)
41 placebo$.tw. (265371)
42 prospective study/ (415317)
43 or/25-42 (1860599)
44 case study/ (51268)
45 case report.tw. (353058)
46 abstract report/ or letter/ (1036148)
47 or/44-46 (1432272)
48 43 not 47 (1813215)
49 15 and 24 and 48 (1488)
50 ("201400" or "201500" or "201600" or "201701" or "201801" or "201802" or "201803").em. (28088822)
51 49 and 50 (1190)
  (Continued)
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Appendix 3. PsycInfo search strategy
 
PsycInfo
1 Addiction/ (9382)
2 Drug dependency/ (12153)
3 Drug Usage/ (16822)
4 Drug Abuse/ (44051)
5 Alcohol Abuse/ (16779)
6 Alcohol rehabiliation/ or drug rehabilitation/ (19802)
7 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (74728)
8 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (176992)
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (241511)
10 crime/ (14125)
11 criminal behavior/ (8381)
12 recidivism/ (5324)
13 prisoners/ or prisons/ or incarceration/ (16728)
14 probation/ or parole/ (1864)
15 criminals/ or female criminals/ or male delinquency/ or juvenile delinquency/ (30689)
16 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (53371)
17 (offend$ or criminal$ or convict$ or felon$).ti,ab. (69723)
18 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (37348)
19 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (8414)
20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (142208)
21 (empirical study or treatment outcome clinical trial).md. (2237461)
22 (random$ adj4 trial$).ti,ab. (44037)
23 Placebo/ (5050)
24 (random* or sham or placebo*).ti,ab,hw. (203386)
25 ((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw. (23778)
26 21 or 22 or 23 or 24 or 25 (2291604)
27 9 and 20 and 26 (11242)
28 (201404$ or 201405$ or 201406$ or 201407$ or 201408$ or 201409$ or 201410$ or 201411$ or 201412$).up. (164403)
29 (2015$ or 2016$ or 2017$).up. (645836)
30 "20180101".up. (957)
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31 28 or 29 or 30 (811196)
32 27 and 31 (2333)
  (Continued)
 
Appendix 4. PASCAL, SciSearch, Social SciSSciSearch, Wilson Applied Science and Technology Abstracts search
strategy
 
PASCAL search
#1TOPIC: (substance* NEAR/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or consumption* or with-
draw* or withdraw* or detox*)) OR TOPIC: (drug* NEAR/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misus-
ing or consumption* or withdraw* or withdraw* or detox*)) OR TOPIC: (narcotic* NEAR/2 (addict* or depend* or disorder* or abuse*
or abusing or misuse* or misusing or consumption* or withdraw* or withdraw* or detox*))
DocType=All document types; Language=All languages;
#2TOPIC: (mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or
cannabis or crack or phencyclidine)
DocType=All document types; Language=All languages;
#3#2 OR #1
DocType=All document types; Language=All languages;
#4TOPIC: ("justice system" or remand* or parole* or probation or court* or corrections or correctional or revocation) OR TOPIC:
(crime or criminal or offender* or criminal* or convict* or felon*) OR TOPIC: (custody or custodial or gaol* or jail* or prison* or incar-
cerat* or inmate*) OR TOPIC: (reoffend* or reincarcerat* or recidiv* or ex-offender*)
DocType=All document types; Language=All languages;
#5#4 AND #2
DocType=All document types; Language=All languages;
 
 
Appendix 5. CENTRAL Register of Controlled trials search strategy via the Cochrane Library
 
CENTRAL search
#1 MeSH descriptor: [Substance-Related Disorders] explode all trees
#2 MeSH descriptor: [Street Drugs] explode all trees
#3 MeSH descriptor: [Designer Drugs] explode all trees
#4 MeSH descriptor: [Narcotics] explode all trees
#5 (substance* or drug* or narcotic*) near/2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or con-
sumption* or withdraw$ or withdraw* or detox*):ti,ab,kw (Word variations have been searched)
#6 mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or cannabis
or crack or phencyclidine:ti,ab,kw (Word variations have been searched)
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Crime] explode all trees
#9 MeSH descriptor: [Criminals] explode all trees
#10 MeSH descriptor: [Prisoners] explode all trees
#11 (justice system) or remand* or parole* or probation or court* or corrections or correctional or revocation:ti,ab,kw (Word varia-
tions have been searched)
 
Interventions for drug-using oenders with co-occurring mental health problems (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
90
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
#12 custody or custodial or gaol* or jail* or prison* or incarcerat* or inmate*:ti,ab,kw (Word variations have been searched)
#13 reoffend* or reincarcerat* or recidiv* or ex-offender*:ti,ab,kw (Word variations have been searched)
#14 offend* or criminal* or convict* or felon:ti,ab,kw (Word variations have been searched)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 #7 and #15
  (Continued)
 
Appendix 6. ASSIA search strategy
 
ASSIA search
(ti(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse*
OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(drug* NEAR/2 (addict* OR depend* OR disorder* OR
abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ab(drug* NEAR/2 (addict*
OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*))
OR ti(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(mdma OR alcohol* OR opiate* OR opioid* OR opium OR
heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack OR phencyclidine) OR ab(mdma OR alco-
hol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack
OR phencyclidine)) AND (ti((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR re-
vocation) OR ab((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR revocation) OR
ti(crime OR offend* OR criminal OR convict* OR felon*) OR ab(crime OR offend* OR criminal* OR convict* OR felon*) OR ti(custody OR
custodial OR gaol* OR jail* OR prison* OR incarcerat* OR inmate*) OR ab(custody OR custodial OR gaol* OR jail* OR prison* OR incar-
cerat*or inmate*) OR ti(reoffend* OR reincarcerat* OR recidiv* OR ex-offender*) OR ab(reoffend* OR reincarcerat* OR recidiv* OR ex-
offender*)).
 
 
Appendix 7. Health Management Information Consortium (HMIC) search strategy via Ovid
 
HMIC
1 designer drugs/ (6)
2 exp narcotics/ (365)
3 ((substance$ or drug$ or narcotic$) adj2 (addict$ or depend$ or disorder$ or abuse$ or abusing or misuse$ or misusing or con-
sumption$ or withdraw$ or withdraw$ or detox$)).ti,ab. (3032)
4 (mdma or alcohol$ or opiate$ or opioid$ or opium or heroin or methadone or cocaine or amphetamine$ or marijuana or cannabis
or crack or phencyclidine).ti,ab. (6910)
5 1 or 2 or 3 or 4 (9003)
6 crime/ (450)
7 prisoners/ (652)
8 (justice system or remand$ or parole$ or probation or court$ or corrections or correctional or revocation).ti,ab. (3327)
9 (offend$ or criminal$ or convict$ or felon$).ti,ab. (2875)
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10 (custody or custodial or gaol$ or jail$ or prison$ or incarcerat$ or inmate$).ti,ab. (2332)
11 (reoffend$ or reincarcerat$ or recidiv$ or ex-offender$).ti,ab. (105)
12 6 or 7 or 8 or 9 or 10 or 11 (7118)
13 5 and 12 (634)
14 limit 13 to yr="2014 -Current" (14)
  (Continued)
 
Appendix 8. PAIS search strategy
 
PAIS
(ti(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(substance* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse*
OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(drug* NEAR/2 (addict* OR depend* OR disorder* OR
abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ab(drug* NEAR/2 (addict*
OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR withdraw* OR withdraw* OR detox*))
OR ti(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR misusing OR consumption* OR with-
draw* OR withdraw* OR detox*)) OR ab(narcotic* NEAR/2 (addict* OR depend* OR disorder* OR abuse* OR abusing OR misuse* OR
misusing OR consumption* OR withdraw* OR withdraw* OR detox*)) OR ti(mdma OR alcohol* OR opiate* OR opioid* OR opium OR
heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack OR phencyclidine) OR ab(mdma OR alco-
hol* OR opiate* OR opioid* OR opium OR heroin OR methadone OR cocaine OR amphetamine* OR marijuana OR cannabis OR crack
OR phencyclidine)) AND (ti((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR re-
vocation) OR ab((justice system) OR remand* OR parole* OR probation OR court* OR corrections OR correctional OR revocation) OR
ti(crime OR offend* OR criminal OR convict* OR felon*) OR ab(crime OR offender* OR criminal* OR convict* OR felon*) OR ti(custody
OR custodial OR gaol* OR jail* OR prison* OR incarcerat* OR inmate*) OR ab(custody OR custodial OR gaol* OR jail* OR prison* OR in-
carcerat*or inmate*) OR ti(reoffend* OR reincarcerat* OR recidiv* OR ex-offender*) OR ab(reoffend* OR reincarcerat* OR recidiv* OR
ex-offender*))
 
 
Appendix 9. Criminal Justice Abstracts search strategy
 
CJA search
S1
TI ( substance* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or
withdraw* or detox*) ) OR AB ( substance* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or con-
sumption* or withdraw* or withdraw* or detox*) ) OR TI ( drug* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse*
or misusing or consumption* or withdraw* or withdraw* or detox*) ) OR AB ( drug* N2 (addict* or depend* or disord ...
Search modes - Boolean/Phrase
S2
TI ( mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or cannabis
or crack or phencyclidine ) OR AB ( mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or ampheta-
mine* or marijuana or cannabis or crack or phencyclidine )
Search modes - Boolean/Phrase
S3
S1 OR S2
Search modes - Boolean/Phrase
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S4
TI ( justice system) or crime or remand* or parole* or probation or court* or corrections or correctional or revocation ) OR AB ( justice
system) or crime or remand* or parole* or probation or court* or corrections or correctional or revocation ) OR TI ( offend* or crimi-
nal* or convict* or felon* ) OR AB ( offend* or criminal* or convict* or felon* ) OR TI ( custody or custodial or gaol* or jail* or prison* or
incarcerat* or inmate* ) OR AB ( custody or custodial or gaol* or jail* or prison* or ...
Search modes - Boolean/Phrase
S5
S3 AND S4
  (Continued)
 
Appendix 10. LILACS
 
LILACS search (via http://lilacs.bvsalud.org/en/).
tw:((remand or prison or prisoner or prisoners or prisäo or cárcere or cárcel or detenidos or detentas or acusados or presidiáriosso-
bre or presidiarias or preso or Privados or recluses or offender$ or infratoras or infratora or infratores or delicuentes or infrator or
criminal$ or probation or probatorio or estagio or court or courts or tribunal or tribunals or secure establishment$ or secure facilit$
or reoffend$ or reincarcerat$ or recidivi$ or reincidencia or recidivante or reincidência or ex-offender$ or jail or jails or gaol or gaols
or incarcerat$ or encarcerados or covict or convicts or convicted or felon or felons or conviction$ or reconviction$ or Convicçöes or
convicciones or inmate$ or internos or high security or prisoners or law enforcement or jurisprudence))) AND (tw:((Substance abuse$
or substance misuse$ or substance use$ or usuários de substâncias or drug dependanc$ or drug abuse$ or drug use$ or drug misuse$
or drug addict$ or narcotics addict$ or narcotics use$ or narcotics misuse$ or narcotics abuse$ or chemical dependenc$ or opiates or
heroin or crack or cocaine or amphetamines or cocaine or heroína or opioides or anfetaminas or opiáceos or opióides or addiction or
adicción or adicciones or dependência or farmacodependente or adición or adiçäo or dependence disorder$ or drug involved or Sub-
stance-related disorders or amphetamine-related disorders or cocaine-related disorders or marijuana abuse or opioid-related disor-
ders or phencyclidine abuse or substance abuse intravenous or street drugs or designer drugs or cocaine or amphetamines or anal-
gesics)))
 
 
Appendix 11. CINHAL Plus
 
S1 TI ( substance* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or misusing or
consumption* or withdraw* or withdraw* or detox*) ) OR AB ( substance* N2 (addict* or depend* or
disorder* or abuse* or abusing or misuse* or misusing or consumption* or withdraw* or withdraw*
or detox*) ) OR TI ( drug* N2 (addict* or depend* or disorder* or abuse* or abusing or misuse* or
misusing or consumption* or withdraw* or withdraw* or detox*) ) OR AB ( drug* N2 (addict* or de-
pend* or disord ...
S2 TI ( mdma or alcohol* or opiate* or opioid* or opium or heroin or methadone or cocaine or am-
phetamine* or marijuana or cannabis or crack or phencyclidine ) OR AB ( mdma or alcohol* or opi-
ate* or opioid* or opium or heroin or methadone or cocaine or amphetamine* or marijuana or
cannabis or crack or phencyclidine )
S3 S1 OR S2
S4 TI ( justice system) or crime or remand* or parole* or probation or court* or corrections or correc-
tional or revocation ) OR AB ( justice system) or crime or remand* or parole* or probation or court*
or corrections or correctional or revocation ) OR TI ( offend* or criminal* or convict* or felon* )
OR AB ( offend* or criminal* or convict* or felon* ) OR TI ( custody or custodial or gaol* or jail* or
prison* or incarcerat* or inmate* ) OR AB ( custody or custodial or gaol* or jail* or prison* or ...
S5 S3 AND S4
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Appendix 12. Criteria for assessing risk of bias
 
 Item  Judgement  Description
Low risk The investigators describe a random component in the sequence generation process
such as random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimisation
High risk The investigators describe a non-random component in the sequence generation process
such as odd or even date of birth; date (or day) of admission; hospital or clinic record
number; alternation; judgement of the clinician; results of a laboratory test or a series of
tests; availability of the intervention
1. Random se-
quence genera-
tion (selection
bias)
 
 
Unclear risk Insufficient information about the sequence generation process to permit judgement of
low or high risk
Low risk Investigators enrolling participants could not foresee assignment because 1 of the follow-
ing, or an equivalent method, was used to conceal allocation: central allocation (includ-
ing telephone, web-based, and pharmacy-controlled, randomisation); sequentially num-
bered drug containers of identical appearance; sequentially numbered, opaque, sealed
envelopes
High risk Investigators enrolling participants could possibly foresee assignments because 1 of the
following methods was used: open random allocation schedule (e.g. a list of random
numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were
unsealed or nonopaque or were not sequentially numbered); alternation or rotation; date
of birth; case record number; any other explicitly unconcealed procedure
2. Allocation con-
cealment (selec-
tion bias)
 
 
Unclear risk Insufficient information to permit judgement of low or high risk. This is usually the case
if the method of concealment is not described or is not described in sufficient detail to al-
low a definitive judgement
3. Blinding of out-
come assessor
(detection bias)
Objective out-
comes 
Low risk
 
 
No blinding of outcome assessment, but the review authors judge that the outcome mea-
surement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that blinding could have been bro-
ken
Low risk
 
No blinding of outcome assessment, but the review authors judge that the outcome mea-
surement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that blinding could have been bro-
ken
High risk No blinding of outcome assessment, and the outcome measurement is likely to be influ-
enced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have been broken, and
the outcome measurement is likely to be influenced by lack of blinding
4. Blinding of out-
come assessor
(detection  bias)
Subjective out-
comes
 
 
Unclear risk Insufficient information to permit judgement of low or high risk
7. Incomplete out-
come data (attri-
tion bias)
Low risk
 
 
No missing outcome data
Reasons for missing outcome data unlikely to be related to true outcome (for survival da-
ta, censoring unlikely to be introducing bias)
 
Interventions for drug-using oenders with co-occurring mental health problems (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
94
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
  Missing outcome data balanced in numbers across intervention groups, with similar rea-
sons for missing data across groups
For dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention ef-
fect estimate
For continuous outcome data, plausible effect size (difference in means or standardised
difference in means) among missing outcomes not enough to have a clinically relevant
impact on observed effect size
Missing data have been imputed through appropriate methods
All randomised participants are reported/analysed in the group they were allocated to by
randomisation, irrespective of non-compliance and co-interventions (intention-to-treat)
High risk Reason for missing outcome data likely to be related to true outcome, with either imbal-
ance in numbers or reasons for missing data across intervention groups
For dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk enough to induce clinically relevant bias in intervention effect estimate
For continuous outcome data, plausible effect size (difference in means or standardised
difference in means) among missing outcomes enough to induce clinically relevant bias
in observed effect size
'As-treated' analysis done with substantial departure of the intervention received from
that assigned at randomisation
For all outcomes
except retention
in treatment or
dropout
 
 
Unclear risk Insufficient information to permit judgement of low or high risk (e.g. number randomised
not stated, no reasons for missing data provided; number of dropout not reported for
each group)
Low risk The study protocol is available and all of the study's prespecified (primary and secondary)
outcomes that are of interest in the review have been reported in the prespecified way
The study protocol is not available, but it is clear that published reports include all ex-
pected outcomes, including those that were prespecified (convincing text of this nature
may be uncommon)
High risk Not all of the study’s prespecified primary outcomes have been reported
1 or more primary outcomes are reported via measurements, analysis methods, or sub-
sets of the data (e.g. subscales) that were not prespecified
1 or more reported primary outcomes were not prespecified (unless clear justification for
their reporting is provided, such as an unexpected adverse effect)
1 or more outcomes of interest in the review are reported incompletely so they cannot be
entered in a meta-analysis
The study report fails to include results for a key outcome that would be expected to have
been reported for such a study
8. Selective re-
porting (reporting
bias)
 
 
Unclear risk Insufficient information to permit judgement of low or high risk
  (Continued)
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Date Event Description
12 March 2019 New search has been performed This update represents an additional 5 trials, bringing the total
number of trials in this review to 13. The search strategies are
complete up until 6 February 2019. The 13 trials represent 2501
participants and 21 publications.
12 March 2019 New citation required but conclusions
have not changed
Conclusions have not changed
 
H I S T O R Y
Review first published: Issue 1, 2014
 
Date Event Description
2 June 2015 Amended Amended the byline
18 May 2015 New citation required but conclusions
have not changed
Conclusions have not changed
11 July 2014 New search has been performed This review has been updated to May 2014. Through this process,
3 trials have been added, bringing the total number of trials for
this review to 8 and representative publications to 14
28 May 2012 New search has been performed This review has been updated using searches to 21 March 2013.
The review represents 1 in a family of 4 reviews. These reviews
cover pharmacological and non-pharmacological interventions
and drug-using female offenders. This review of interventions
with drug-using offenders with co-occurring mental illness con-
tains 5 randomised controlled trials. These trials represent a to-
tal of 1502 participants
2 October 2011 New search has been performed The updated version of this review produced a new document
with additional findings reflecting searches up to 11 November
2011. Five new authors have been added to this version of the re-
view. These include Steven Du-y, Rachael McCool, Matthew Neil-
son, Catherine Hewitt, and Marrissa Martyn-St James
1 July 2011 Amended This review has been converted to new review format
8 June 2011 New search has been performed This review has been substantially updated
19 May 2006 New citation required and conclusions
have changed
Substantive amendments have been made
 
C O N T R I B U T I O N S   O F   A U T H O R S
Searches were constructed and conducted by KW. The independent review team inspected the search hits by reading titles and abstracts.
Each potentially relevant study located in the search was obtained as a full article and was independently assessed for inclusion by the
review team. In the case of discordance, a third independent review author arbitrated. When it was not possible to evaluate the study
because of language problems or missing information, it was classified as 'translation/information required to determine decision' until a
translation or further details were provided. The team of review authors conducted data extraction for these papers. Results were compiled
and organised by AEP, LB, and CH, the review team, and all review authors contributed towards the final draC text.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We decided to limit our search for this update on studies on effectiveness, because we verified from previous updates that the data on cost
and cost-effectiveness are too sparse and heterogeneous to provide any meaningful information. Performance bias was not assessed.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Case Management;  Crime  [prevention & control]  [statistics & numerical data];  Diagnosis, Dual (Psychiatry);  Law Enforcement;  Mental
Disorders  [*therapy];  Motivational Interviewing;  Psychotherapy;  Randomized Controlled Trials as Topic;  Substance-Related Disorders
 [*therapy];  Therapeutic Community
MeSH check words
Adolescent; Adult; Female; Humans; Male; Young Adult
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